



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61L 15/44	A3	(11) International Publication Number: WO 96/40086 (43) International Publication Date: 19 December 1996 (19.12.96)
(21) International Application Number: PCT/US96/08294 (22) International Filing Date: 5 June 1996 (05.06.96) (30) Priority Data: 08/477,361 7 June 1995 (07.06.95) US (60) Parent Application or Grant (63) Related by Continuation US 08/477,361 (CIP) Filed on 7 June 1995 (07.06.95) (71) Applicant (for all designated States except US): NOVEN PHARMACEUTICALS, INC. [US/US]; 11960 S.W. 144th Street, Miami, FL 33186 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): KANIOS, David, P. [US/US]; 10651 Hammocks #838, Miami, FL 33196 (US). GENTILE, Joseph, A. [US/US]; 5751 Rose Terrace, Plan- tation, FL 33317 (US). MANTELLE, Juan, A. [US/US]; 10821 Southwest 92nd Avenue, Miami, FL 33176 (US). SABLITSKY, Steven [US/US]; 9245 S.W. 118th Terrace, Miami, FL 33176 (US).	(74) Agents: MELOY, Sybil et al.; Foley & Lardner, Suite 500, 3000 K Street, N.W., Washington, DC 20007-5109 (US). (81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the</i> <i>claims and to be republished in the event of the receipt of</i> <i>amendments.</i> (88) Date of publication of the international search report: 13 February 1997 (13.02.97)	
(54) Title: COMPOSITIONS AND METHODS FOR TOPICAL ADMINISTRATION OF PHARMACEUTICALLY ACTIVE AGENTS (57) Abstract Compositions for topical application comprising a therapeutically effective amount of a pharmaceutical agent(s), a pharmaceutically acceptable bioadhesive carrier, a solvent for the pharmaceutical agent(s) in the carrier and a clay, and methods of administering the pharmaceutical agents to a mammal are disclosed.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 96/08294

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61L15/44

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61L

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 91 14463 A (NOVEN PHARMA) 3 October 1991 see page 5, paragraph 3 see page 7, paragraph 2 see page 25; table 1 ---	1,4,5
X	EP 0 598 606 A (JOHNSON & JOHNSON CONSUMER) 25 May 1994 see page 10; example 7 ---	1
A	WO 92 15289 A (NOVEN PHARMA) 17 September 1992 see the whole document ---	1-27
A	DE 30 39 540 A (HOLLISTER INC) 7 May 1981 see page 4, paragraph 1 - page 5, paragraph 1 ---	1-27
-/--		

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

13 December 1996

Date of mailing of the international search report

20.12.96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Boulois, D

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 96/08294

C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 95 01766 A (CYGNUS THERAPEUTIC SYSTEMS ;WONG 001 (US); FARINAS KATHLEEN COGAN) 19 January 1995 see page 10, line 21 - line 30 ---	1
A	FR 2 479 002 A (BIOTROL SA LAB) 2 October 1981 see page 3, line 8 - line 16 see page 6, line 1 - line 7 -----	1-27

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 96/08294

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim(s) 23-27
is(are) directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 96/08294

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9114463	03-10-91	EP-A- 0474647	18-03-92
EP-A-0598606	25-05-94	AU-A- 5070893	02-06-94
		BR-A- 9304760	14-06-94
		CA-A- 2103306	19-05-94
		CN-A- 1098009	01-02-95
		GR-A- 93100452	29-07-94
		JP-A- 6225932	16-08-94
WO-A-9215289	17-09-92	US-A- 5234957	10-08-93
		AT-T- 144704	15-11-96
		AU-B- 658870	04-05-95
		AU-A- 1461092	06-10-92
		AU-A- 2833195	28-09-95
		CA-A- 2104474	28-08-92
		DE-D- 69214938	05-12-96
		EP-A- 0573576	15-12-93
		EP-A- 0728477	28-08-96
		JP-T- 6508820	06-10-94
		NO-A- 933296	01-11-93
		US-A- 5332576	26-07-94
		US-A- 5446070	29-08-95
DE-A-3039540	07-05-81	AU-B- 526824	03-02-83
		AU-A- 6315880	07-05-81
		BE-A- 885895	27-04-81
		CA-A- 1148083	14-06-83
		FR-A- 2468355	08-05-81
		GB-A,B 2063283	03-06-81
		JP-C- 1353307	11-12-86
		JP-A- 56089252	20-07-81
		JP-B- 61021103	26-05-86
		NL-A,B,C 8005990	01-06-81
		SE-B- 450626	13-07-87
		SE-A- 8007656	03-05-81
		AR-A- 225781	30-04-82
		US-A- 4534767	13-08-85
WO-A-9501766	19-01-95	AU-A- 7323794	06-02-95
		EP-A- 0708627	01-05-96

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 96/08294

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
FR-A-2479002	02-10-81	NONE	

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 9/70	A2	(11) International Publication Number: WO 96/40086 (43) International Publication Date: 19 December 1996 (19.12.96)
(21) International Application Number: PCT/US96/08294 (22) International Filing Date: 5 June 1996 (05.06.96) (30) Priority Data: 08/477,361 7 June 1995 (07.06.95) US (60) Parent Application or Grant (63) Related by Continuation US 08/477,361 (CIP) Filed on 7 June 1995 (07.06.95) (71) Applicant (for all designated States except US): NOVEN PHARMACEUTICALS, INC. [US/US]; 11960 S.W. 144th Street, Miami, FL 33186 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): KANIOS, David, P. [US/US]; 10651 Hammocks #838, Miami, FL 33196 (US). GENTILE, Joseph, A. [US/US]; 5751 Rose Terrace, Plantation, FL 33317 (US). MANTELLE, Juan, A. [US/US]; 10821 Southwest 92nd Avenue, Miami, FL 33176 (US). SABLOTSKY, Steven [US/US]; 9245 S.W. 118th Terrace, Miami, FL 33176 (US).	(74) Agents: MELOY, Sybil et al.; Foley & Lardner, Suite 500, 3000 K Street, N.W., Washington, DC 20007-5109 (US). (81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>	
(54) Title: COMPOSITIONS AND METHODS FOR TOPICAL ADMINISTRATION OF PHARMACEUTICALLY ACTIVE AGENTS		
(57) Abstract <p>Compositions for topical application comprising a therapeutically effective amount of a pharmaceutical agent(s), a pharmaceutically acceptable bioadhesive carrier, a solvent for the pharmaceutical agent(s) in the carrier and a clay, and methods of administering the pharmaceutical agents to a mammal are disclosed.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

**COMPOSITIONS AND METHODS FOR TOPICAL ADMINISTRATION
OF PHARMACEUTICALLY ACTIVE AGENTS**

BACKGROUND OF THE INVENTION

Field of the Invention

5 The present invention relates to compositions and
methods for the topical administration of
pharmaceutically active agents to a mammal in need
thereof. More particularly, the present invention relates
to anesthesia and local anesthetic agents for topical
10 administration. Still more particularly, the invention
relates to a method for the topical administration of an
anesthetic agent or a combination of anesthetic agents to
prevent or ameliorate pain.

There is no limitation on the type of pharmaceutical
15 agent that can be used in the present invention, provided
that it can be absorbed topically, typically
percutaneously. Thus, the pharmaceutical agent includes
both drugs that are topically applied for local effects
and those which can be administered topically for
20 systemic effects.

Description of Background Art

Anesthetic agents are pharmacologically active agents
that block nerve conduction when applied in
therapeutically effective amounts. They can be used for
25 local or systemic application. Anesthetic agents have
been used extensively in the medical field to obtain
topical anesthesia. The term "topical" or "topically" is
used here in its conventional sense as referring to a
spot, which can be in or on any part of the body,
30 including but not limited to the epidermis, any other
dermis, or any other body tissue. Topical administration
or application means the direct contact of the anesthetic
with tissue, such as skin or membrane, particularly the
oral or buccal mucosa. Topical administration also
35 includes application to hardened tissue such as teeth and
appendages of the skin such as nails and hair. Previous
methods of applying topical anesthetic agents to the skin
or mucosa have used "non-finite" or liquid or semi-liquid

carriers such as gels, lotions, emulsions, creams, plasters, or ointments, or "finite" carriers, non-spreading substances which retain their form, e.g. patches, dressings and bandages.

5 Local anesthetics generally are esters or amides of benzoic acid derivatives, administered either as the free base or the acid-addition salt. Free bases tend to be irritating at high concentrations. Acid-addition salts have low skin permeability.

10 To be effective, a topical, local anesthetic should contain sufficient concentration of the active agent to produce an anesthetic effect, it should penetrate the tissue such as intact skin or mucosa sufficiently to deliver a therapeutic dose, and it should exhibit rapid
15 onset of anesthetic action and have a prolonged anesthetic effect. In achieving the foregoing, it is often desirable to have the anesthetic agent present in a high concentration to effect a rapid onset and, additionally or alternatively, in excess of the amount
20 that can be immediately absorbed through the dermis at the site of application, so as to prolong anesthesia. On the other hand, the presence of the anesthetic agent primarily in crystalline form may irritate sensitive tissues such as mucosal tissues. This is particularly
25 true with regard to lidocaine.

U.S. Serial Number 08/112,330, now U.S. Patent No. 5,466,070, granted August 29, 1995, discloses and claims a drug in bioadhesive containing a solvent for the drug and a plasticizer for the bioadhesive. It has
30 surprisingly been found that incorporation of a clay into the composition increased its cohesiveness.

SUMMARY OF THE INVENTION

The invention relates to a flexible, finite, bioadhesive composition for topical application
35 comprising:

(a) a therapeutically effective amount of at least one pharmaceutically active agent;

(b) a pharmaceutically acceptable solvent for the pharmaceutically active agent and a plasticizer;

(c) in admixture with the pharmaceutically active agent in the solvent, a pharmaceutically acceptable bioadhesive carrier in an amount from about 20 to about 50 weight percent based on the weight of the whole composition; and

(d) a cohesiveness increasing amount of a clay;

wherein the composition is substantially free of water, substantially water insoluble and is a bioadhesive; and wherein the pharmaceutically active agent is present in non-crystallized form in the composition.

These compositions may further comprise a backing material which conforms to the size and shape of a single dosage of the composition.

This invention also relates to a method of administering the foregoing compositions.

The invention relates to method of administering one or more pharmaceutically active agents in a bioadhesive to a subject comprising the steps of:

(a) providing a flexible, finite, bioadhesive composition for topical application comprising a therapeutically effective amount of at least one pharmaceutically active agent;

a pharmaceutically acceptable solvent for the pharmaceutically active agent, and a plasticizer;

in admixture with the pharmaceutically active agent in the solvent, a pharmaceutically acceptable polysaccharide bioadhesive, preferably a polysaccharide bioadhesive, carrier in an amount from about 20 to about 50 weight percent based on the weight of the whole composition; and a cohesiveness increasing amount of a clay;

wherein the composition is substantially free of water, substantially water insoluble and is a bioadhesive; and wherein the pharmaceutically active

agent is present in non-crystallized form in the composition; and

- (b) contacting an area of skin or mucous membrane with the composition to administer the pharmaceutically active agent.

DETAILED DESCRIPTION OF THE INVENTION

This invention provides a composition which when administered topically, for example to an area of the skin, skin appendage, teeth or mucosa, delivers a pharmaceutical agent or a combination of agents to produce a local or systemic effect over a prolonged period of time.

In accordance with one embodiment of the present invention, a pharmaceutically active agent and a plasticizer for the adhesive are in admixture with a pharmaceutically acceptable adhesive, which is preferably a bioadhesive, and more preferably a polysaccharide bioadhesive, and a cohesiveness increasing amount of clay, is provided in a finite, flexible form for topical application to the skin or dermal membrane of a mammal. Preferably, the pharmaceutically active agent is in solid form at ambient temperatures and pressures.

In accordance with a further embodiment of the present invention, a combination of local anesthetic agents, a solvent for the anesthetic agents and a finite or non-finite, fluid or flexible, pharmaceutically acceptable carrier is provided for topical application to a tissue, for example the skin or mucosa of a mammal.

The anesthetic agents of this invention are those known, or of a type known, in the art. The local anesthetic bases encompassed by this invention are weak organic bases which are lipophilic in nature and thus poorly soluble in water. However, these bases will react with organic or inorganic acids to form acidic, water soluble acid addition salts. Thus, the term "base" as used herein means the un-ionized form of the anesthetic that can furnish an electron pair to form a covalent bond. The term "acid" as used herein is a substance that

can take up an electron pair to form a covalent bond. The term "salt" as used herein means the form produced by a base, for example an anesthetic base, upon its reaction with an organic or inorganic acid.

5 The base form and the salt form of the anesthetic agent incorporated in the present combination composition are desirably different anesthetic agents to achieve maximum duration of the combined anesthetic effect. By the term "different" is meant that the salt form in any
10 combination is not a salt of the base form used in the given combination.

Local anesthetic agents suitable for use in the practice of this invention include amides and esters. Examples of the amides are lidocaine, prilocaine,
15 mepivacaine, bupivacaine, dibucaine and etidocaine. Esters include procaine, tetracaine, propoxycaine, chlorprocaine, benzocaine, butamben picrate, cocaine, hexylcaine, piperocaine, oxyprocaine and proparacaine. Other suitable local anesthetics for use in the practice
20 of this invention include cyclomethycaine, dimethisoquin, ketocaine, dipiperodon, dyclonine and pramoxine, all typically administered in the form of the acid addition hydrochloride or sulfate salts.

The acid-addition salts of the present invention are
25 any non-toxic, pharmaceutically acceptable organic or inorganic salts. Typical inorganic salts are the hydrogen halides, especially the hydrochlorides, carbonates, borates, phosphates, sulfates, hydrogen sulfates, hydrobromides, nitrates, sulfides, and
30 arsenates. Typical organic salts are salts of mono- and polycarboxylic acids such as the citrate, tartrate, malate, cinnamate, oxalate, formate, succinate and phthalates. The term "non-salicylate" used herein means that in certain embodiments, the acid addition salts do
35 not include salts of esters of salicylic acid and its analogs such as aspirin.

The solvents for the finite and non-finite forms of the active agents are non-toxic, pharmaceutically

acceptable substances, preferably liquids, which do not substantially negatively affect the adhesion properties or solubility of the system. The solvent is preferably a polyhydric alcohol or combination of polyhydric alcohols. The term polyhydric alcohol means any organic polyalcohol and includes dipropylene glycol, propylene glycol, polyethylene glycol, glycerin, butylene glycol, hexylene glycol, polyoxyethylene, polypropylene glycol, sorbitol, ethylene glycol, and the like. Other suitable solvents include fatty acids such as oleic acid, linoleic acid, capric acid and the like, as well as fatty esters or alcohols. Further suitable solvents include other non-toxic, non-volatile solvents commonly used in dermal or transdermal compositions for dissolving like compounds.

The above mentioned polyhydric alcohols may include those having 2 to 6 alcoholic hydroxyl groups. Such polyhydric alcohols include glycols, triols and polyols having 4 to 6 alcoholic hydroxyl groups. Typical of said glycols are glycols containing 2 to 6 carbon atoms, e.g. ethylene glycol, propylene glycol, butylene glycol, polyethylene glycol (average molecular weight about 200 - 8,000, preferably about 200 to 6,000), etc. Examples of said triols include glycerin, trimethylolpropane, etc. Said polyols are exemplified by sorbitol (sorbit), polyvinylpyrrolidone, etc. These polyhydric alcohols may be used either singly or in combination (preferably, of two or three). Thus, for example, glycerin alone or a mixture of glycerin and butylene glycol is employed.

Among those polyhydric alcohols, those which satisfy the requirements relevant to the adjustment and maintenance of softness of the external surface of the invention, the compatibility or co-dispersibility with the other components, and provide a proper consistency of the composition, may be freely used. Those which are low in volatility are generally preferred and, in this regard, dipropylene glycol, glycerin, propylene glycol,

butylene glycol, and sorbitol are appropriate solvents, according to the invention.

Although the exact amount of the polyhydric alcohols in the composition depends on the nature of other components, and therefore cannot be stated in general terms, the proportion may range from about 5 to about 50 weight percent based on the whole composition, and depending on the amount of other ingredients.

In one embodiment, the solvent is in an amount from about 20 to 50 weight percent based on the weight of the whole composition. The solvent includes from about 5% to about 50%, and more preferably about 10% to 30% of a solvent known to plasticize the bioadhesive carrier. A particularly useful plasticizer is glycerine.

The addition of clay has been found to improve cohesiveness of the bioadhesive in transdermal formulations without reducing the rate of drug delivery. Suitable clays include kaolinites such as boalinite, anauxite, dickite and nacrite, montmorillonites such as montmorillonite, bentonite, bordellite and montronite, illites/muscovites such as illite and glauconite, chlorites, polygorshites such as attapulgite, halloysite, metaballoysite, allophane and aluminum silicate clays. Especially useful are smectite clays. The clay may be natural or synthetic. An especially useful synthetic hectorite clay is Laponite XLG, the chemical name of which is hydrous sodium lithium magnesium silicate (Southern Clay Products, Inc.; Gonzales, TX; 78629 and Laporte Absorbents; P.O. Box 2, Moorfield Road; Widnes; WA8 OJU). The use of metal oxides such as magnesium oxide, zinc oxide, and titanium oxide with the clay tends to increase the cohesiveness of the preparation.

The clay is used in a cohesiveness increasing amount, namely about 0.5 to about 20%, preferably about 0.5 to about 10%, and more preferably, about 1 to about 7%, of the total composition. The metal oxides are conveniently used in amounts from about 0.1 to about 1%, but can be used in greater or lesser amounts. The addition of clay

is based on the surprising finding that the addition of a clay to a bioadhesive results in an increase in viscosity, swelling and gelling of the adhesive matrix such that it permits reduction of the amount of bioadhesive on greater than a weight for weight basis.

The high concentrations of microdispersed active agent of this invention are achieved typically by mixing the agents with the solvent, preferably at an elevated temperature, for example about 70 to 100°C, to obtain a mixture, preferably a solution, of the agents which is then added to the pharmaceutically acceptable carrier.

The term "microdispersed" is intended to mean that in the solvent, and subsequently the carrier, there is an intimate dispersion of the pharmaceutically active agent at the molecular or ionic level, such that crystals of the pharmaceutically active agent cannot be detected using a microscope having a magnification of 25X. As such, the pharmaceutically active agent is in "non-crystallized" form when in the compositions of the present invention.

Preferably the pharmaceutically active agent is substantially dissolved in the solvent so that when mixed with the finite adhesive or non-finite fluid carrier, the agent is microdispersed in the composition.

Solvent selection for the active agents depends on the form of the active agent, namely whether it is in free base form or acid-addition salt form. Solvents for the salt form of active agents are polar organic solvents. Polar organic solvents are preferably polyhydric alcohols, as discussed above. Various other solvents suitable for either the base or acid-addition form of the active agent are those solvents known to dissolve either or both of these two types of forms including cyclic ketones such as 2-pyrrolidone; N-(2-hydroxyethyl) pyrrolidone, N-methylpyrrolidone, 1-dodecylazacycloheptan-2-one and other n-substituted alkylazacycloalkyl-2-ones (azones) dimethylformamide, and dimethylsulfoxide. Other suitable solvents for the free

base form of the active agent are cell envelope disordering compounds known to be useful in topical pharmaceutical preparations, which compounds are thought to assist in skin penetration by disordering the lipid structure of the stratum corneum cell-envelopes. Some of these compounds are generally encompassed by the formula:

R-X

wherein R is a straight-chain alkyl of about 7 to 16 carbon atoms, a non-terminal alkenyl of about 7 to 22 carbon atoms, or a branched-chain alkyl of from about 13 to 22 carbon atoms, and X is -OH, -COOCH₃, -COOC₂H₅, -OCOCH₃, -SOCH₃, -P(CH₃)₂O, -COOCH₂H₄OC₂H₄OH, -COOCH(CHOH)₄CH₂OH, -COOCH₂CHOHCH₃, -COOCH₂CH(OR'')CH₂OR'', -(OCH₂CH₂)_mOH, -COOR', or -CONR'₂, where R_i is -H, -CH₃, -C₂H₅, -C₃H₇ OR -C₂H₄OH; R'' is -H, or a non-terminal alkenyl of about 7 to 22 carbon atoms; and m is a positive integer from 2 to 6; provided that when R'' is an alkenyl and X is -OH or -COOH, at least one double bond is in the cis-configuration.

It has been discovered that high concentrations of a combination of microdispersed active agents, namely up to 50% by weight of the optionally finite, flexible composition, require the use of a solvent as herein described. In one embodiment of the invention, the active agent(s) is in an amount of from 10 to 40 weight percent based on the weight of the total composition. Omission of the solvent in the procedure of Example 1 below yields a product filled with crystals or a crystalline mass.

In particularly preferred embodiments of this invention, the active agent is an anesthetic. Preferably, it is a free base and salt form of an anesthetic. The free base local anesthetic agent is selected from the group comprising lidocaine, procaine, propoxycaine, mepivacaine, prilocaine, dyclonine, pramoxine, benzocaine and chlorprocaine. The salt form is preferably one selected from the group comprising prilocaine, tetracaine, bupivacaine, dyclonine, dibucaine, etidocaine and lidocaine salts. The aforementioned bases and salts can be used alone or in combination with other anesthetic bases and salts as needed to achieve therapeutically effective levels when administered transdermally, or through other topical route.

The term "therapeutically effective amount" is intended to mean the amount of drug sufficient to produce an anesthetic effect when applied topically. These amounts are known in the art or may be determined by methods known in the art, and typically range from about 1 to 20,000 mg per human adult and preferably about 10 to 10,000 mg and most preferably range from about 20 to 5,000 mg of the anesthetic agent per application, depending upon the anesthetic agents chosen, and whether the tissue, such as the skin or mucous membrane is the site of action. The only upper limit on the amount of anesthetic in the composition is that the preparation is substantially free of crystals of anesthetic agent and

the amount of solvent used is not sufficient to undesirably affect the adhesive properties of the finite composition. Thus, the single ingredient anesthetic agent contains a therapeutically effective amount of anesthetic agent within the foregoing range.

The concentration as well as the quantity of anesthetic per unit area, namely per square or cubic centimeter can be varied independently in order to achieve the desired effect. Higher concentrations of anesthetic base contained in a dosage form of decreased thickness will result in an anesthetic with fast onset and short duration. High concentrations of the anesthetic base contained in a dosage form of increased thickness (higher mg of anesthetic per square or cubic centimeter) will result in potent anesthesia with fast onset and long duration. Low concentrations of the anesthetic base in a dosage form of decreased thickness will result in mild anesthesia with longer onset and short duration. Low concentrations of the anesthetic base contained in a dosage form of increased thickness will have mild anesthesia with longer onset and longer duration. As shown in the above explanation, the ability to vary the concentration of anesthetic from very low (about 1%) to high (40% or higher) of the total composition, when combined with the ability to coat thin (about 0.001 inches) or thick (about 0.500 or more inches) enables the practitioner of the invention to vary the dosage of the system as needed for particular anatomical sites of interest.

As a general rule, in the case of a given tissue, e.g. the mucosal application, the anesthetic drug selected, the concentration and thickness and the duration of the application is determined based upon the anesthetic's ability to penetrate the tissue, for example mucosa, and to be at peak effectiveness within about 2 to 30 minutes. The duration of the effect of the anesthetic on the tissue, for example the oral mucosa, should range between about 2 to 240 minutes, depending on the

anesthetic agent selected, the concentration of the anesthetic and the thickness of application. Longer or shorter durations can also be selected dependent on need, as will be apparent to one skilled in the art.

5 The ratio of the free base form to the salt form in the composition of this invention will depend on several factors, namely: (1) the identity of the salt and base used; (2) the desired duration of action; and (3) the
10 desired rapidity of anesthetic effect. As a general rule in the case of mucosal application, the ratios of base to salt are such that the free base form preferably should penetrate the mucosa and be at its peak effectiveness within about a 2 to 30 minute period, whereas, the salt
15 form should preferably penetrate the mucosa and be at its peak effectiveness within a period of about 10 to 75 minutes. The duration of the effect of these on the oral mucosa will range between about 2 to 240 minutes depending on the base/salt combination selected and the length of application time. In practice to achieve this
20 effect, the amount by weight base form will be in excess of the amount by weight of the salt form.

 The term "onset of anesthesia" is intended to mean the time to peak effect on the individual nerves. Onset of anesthesia principally depends upon the lipid
25 solubility, molecular size, and quantity of available, un-ionized form of the local anesthetic. Thus, anesthetics with a high lipid solubility or a low pK_a , or both, have a more rapid onset of anesthesia.

 The term "duration of anesthesia" as used herein
30 means the period of time during which the local anesthetic measurably blocks nerve conduction. The foregoing depends upon all of the factors listed for onset of anesthesia, as well as on the extent of protein binding of the anesthetic agent.

35 The anesthetic agent free base can penetrate intact skin to a limited degree, and will more rapidly penetrate the skin if the keratin layers are abraded. In the case of the oral mucosa, the anesthetic base will penetrate

much more readily due to the different keratin composition and the resulting difference in the hydrophilicity as compared to the stratum corneum of intact skin.

5 As a general rule, the salt forms of the aforementioned anesthetics do not appreciably penetrate intact skin, but the un-ionized base form do penetrate to a limited degree. Both forms, salt and base, will penetrate abraded keratin layers. The salt as well as
10 the base will penetrate, to a differing degree, the buccal mucosa due to the buccal mucosa's hydrophilicity, as compared to the stratum corneum of intact skin. Generally, the higher the lipid content of the mucosal membrane, the more rapidly the base form of the
15 anesthetic agent will be absorbed. Therefore, when the composition is used for application to oral or buccal mucosa, the different lipid contents of the gum (gingiva) and the alveolar mucosa must be kept in mind in order to obtain the optimal penetration rate.

20 Although applicants do not intend to be bound by any theory or proposed mechanism of operation, it is believed that the base which is lipid soluble has a rapid onset of anesthesia since it enters the lipo-protein nerve membrane preventing the depolarization and ion exchange
25 involved in stimulus conduction. On the other hand, the salt which is not lipid soluble, penetrates to the lipo-protein nerve membrane only after the buffering capacity of the skin or mucosal tissue converts the salt to the base, the final result being a delayed onset of
30 anesthesia.

 The salts of this invention are selected on the basis of onset of anesthesia and duration of anesthesia. Adjusting the ratio of base to salt affects the relative onset as well as the duration of anesthetic action. The
35 greater the amount of anesthetic agent having a rapid onset of action, the shorter the onset of anesthesia. Similarly, the greater the amount of the anesthetic agent having a prolonged duration of anesthesia, the more

prolonged the duration of anesthesia. More than two anesthetic agents may be used to have a broader spectrum of activity. Moreover, the composition can include other drugs used concomitantly.

5 Generally, the concentration of solubilized pharmaceutically active agent can range, on a weight basis, between about 1 and about 50%, preferably between about 2.5 and about 40% and more preferably between about 5 and about 30% of the total weight of the composition.

10 In a preferred embodiment of the invention, the concentration of the dissolved drug is between about 5% and about 20% by weight of the total composition. The base used in the preferred embodiment for a single ingredient preparation is lidocaine.

15 Generally, for the combination of anesthetics, the ratio by weight of base to salt is about 90:10 to about 60:40, preferably about 75:25 to about 60:40, and more preferably about 70:30 to about 60:40. For other salts, the ratios are comparable based on relative molar

20 amounts. Generally, the ratio by weight of base to salt is more than 1:1. In a preferred embodiment of the invention, the ratio is about 2:1 base to salt, respectively. The base used in the preferred embodiment is lidocaine and the preferred salt is a salt of

25 prilocaine, bupivacaine, dyclonine, mepivacaine, or tetracaine, preferably the hydrochloride salt.

Table 1 below summarizes the peak and duration of action of selected local anesthetics based primarily on application to skin or mucous membranes:

TABLE 1

	Local Anesthetic	Minimum Adult Dose	Maximum Adult Dose (mg)	Peak Effect (minutes)	Duration of Effect (minutes)
5	Dibucaine		25	< 15	120-240
	Lidocaine		750	2-5	30-60
	Benzocaine		5000	1	30-60
	Cocaine		50	2-5	30-120
	Tetracaine		50	3-8	30-60
10	Dyclonine		100	< 10	< 60
	Pramoxine		200	3-5	NA

NA: Not Available.

Source: Drug Facts and Comparisons, 1990 edition,
J.B. Lippincott Company, St. Louis, MO. Page
601.

15 In general, the relative speed of onset of anesthesia and duration of anesthesia for any given form of anesthetic agent is available in the literature or can be calculated by standard tests.

20 Onset time, as well as duration of anesthesia, will vary from individual to individual as well as on the basis of the site of application. When applying the composition to highly keratinized dermal tissues, the onset of anesthesia may take as long as 2 to 4 hours.

25 The composition of this invention can be manufactured by numerous methods known in the art which permit the achievement of a microdispersed anesthetic agent, including extruding, molding, solvent casting, coating, and all other methods which employ a solvent to disperse the drug in a finite or non-finite carrier.

30 In one embodiment of the invention, the composition comprises a combination of a first anesthetic agent in the form of a base and a second anesthetic agent in the form of an acid-addition salt. In this embodiment, the term "pharmaceutically acceptable carrier" is intended to
35 be any suitable finite or non-finite carrier including liquids, semi-liquids or solid carriers, such as a bioadhesive. Thus, the active agents may be admixed with a non-adhesive tape or other finite carrier or a carrier such as a cream, gel, emulsion, lotion, salve, paste,

plaster, ointment, spray-solution, or any other "non-finite" carrier known in the art of pharmaceutical delivery. For example, the base of a non-finite carrier may be fatty oils, lanolin, vaseline, paraffins, glycols,
5 higher fatty acids and higher alcohols.

Contrary to the typical method for manufacturing a drug in a solvent containing adhesive, the adhesive composition of this invention contains a non-volatile solvent. Thus the composition is either not dried to
10 prevent removal of the solvent from the adhesive or a solvent is used at least part of which is not substantially evaporated during the conditions of manufacture. The composition in question can then be applied to a flexible backing or a combination of
15 backings which will serve to define the size and shape of a single dosage of the composition. Such backing may be a three dimensional material such as paper, a non-woven fabric or a natural or synthetic polymer substance. Methods of coating backings are well-known in the art and
20 include techniques involving Mayer rod, gravure, and knife-over roll. Further processing of backings may involve the use of converting equipment for die cutting.

The finished dosage form will be substantially occlusive to water permeation in *in vivo*.

25 For example, in one embodiment, the anesthetic agents are dissolved in a solvent, preferably a polyhydric alcohol, and then the resulting mixture is added to an adhesive prior to being placed onto the flexible form or backing. In another embodiment, the resulting mixture is
30 an cream, gel, emulsion, lotion, salve, plaster, paste, ointment, spray-solution or other "non-finite" composition. The final form in which the composition of the invention will be applied depends upon the anatomical site of application and ease of access.

35 The phrase "flexible, finite, pharmaceutically acceptable carrier" is intended to mean a solid capable of conforming to a surface with which it comes into contact and which is capable of maintaining the contact

so as to facilitate topical application without any adverse physiological response, and which can be used to establish the compositions herein in their preferred solid form without being appreciably decomposed by aqueous contact during administration to a patient.

An important characteristic of the embodiment of the present invention wherein a bioadhesive carrier is employed, relates to the substantially water-free and water-insoluble nature of the composition. By the term "substantially water-free" is meant that the preparation contains less than about 10% by weight water, and preferably less than about 5%, and most preferably less than about 3%. In general, it is desirable to avoid the addition of water entirely and to eliminate, as far as possible, the presence of water in the other ingredients of the composition. By the term "substantially water insoluble" is meant that the composition remains "finite" and does not generally detach from the skin, dermal membrane or other tissue at the site of application and under the conditions of regular, intended use for a period of at least 3 hours. The advantages to be derived from the substantially water-free and water-insoluble nature of the compositions of the present invention include achievement of higher concentrations of drug. Another advantage of these compositions is minimization of precipitation of drug, which precipitation affects processing of the composition, affects rate of delivery of the drugs and in certain cases can affect sensitivity of the subject to be treated to the drug.

Suitable adhesive carriers include any of the non-toxic polymers, particularly those of the type used to carry drugs for transdermal delivery including natural or synthetic elastomers, such as polyisobutylene, styrene, butadiene, styrene isoprene block copolymers, acrylics, urethanes, silicones, styrene butadiene copolymers, methyl acrylate copolymers, acrylic acid, polyacrylates, and polysacchrides such as, karaya gum, tragacanth gum, pectin, guar gum, cellulose, and cellulose derivatives

such as methyl cellulose, propyl cellulose, cellulose acetate and the like, along with other substances known for use in transdermal preparations capable of forming a solid colloid that can adhere to tissue, used alone or in combination with other suitable carriers. A particularly preferred carrier is a bioadhesive for application to the dermis, preferably the mucosa.

The adhesive can be modified so as to adhere to the skin or mucosal tissue, depending on the intended application site. As stated above, preferred adhesives for application to the skin are bioadhesives.

The term "adhesive" as used herein means a substance, inorganic or organic, natural or synthetic, that is capable of surface attachment to the intended application site.

The term "bioadhesive" as used herein means an adhesive which attaches and preferably strongly attaches to a live or freshly killed biological surface such as skin or mucosal tissue upon hydration. Indeed, to qualify as a bioadhesive, a substance must be capable of maintaining adhesion in moist or wet in in vivo or in vitro environments. The final finite composition of the present invention is "self-adhesive" in that it attaches to the site of interest without the need to reinforce its attachment by way of another adhesive which is applied to a backing.

The strength of adherence can be measured by standard tests for measuring the force, e.g. in dynes per square centimeter, as disclosed in U.S. 4,615,697. Suitable bioadhesives include those prepared from optionally partially esterified polyacrylic acid polymers, including but not limited to, polyacrylic acid polymers lightly crosslinked with a polyalkenyl polyether such as those commercially available from B.F. Goodrich, Cincinnati, Ohio, under the trademarks Carbopol 934, 934P, 940 and 941.

Other suitable bioadhesives include natural or synthetic polysaccharides. The term "polysaccharide" as

used herein means a carbohydrate decomposable by hydrolysis into two or more molecules of monosaccharides or their derivatives. Suitable polysaccharides include cellulose derivatives such as methylcellulose, cellulose acetate, carboxymethylcellulose, hydroxyethylcellulose and the like. Other suitable bioadhesives are pectin, a mixture of sulfated sucrose and aluminum hydroxide, hydrophilic polysaccharide gums such as natural plant exudates, including karaya gum, ghatti gum, tragacanth gum, xanthan gum, jaraya gum and the like, as well as seed gums such as guar gum, locust bean gum, psillium seed gum and the like. The term non-finite carrier refers to any liquid or semi liquid known for or suitable for use in pharmaceutical preparations as will be apparent to one skilled in the art.

In addition to the above ingredients, there may also be incorporated other additives selected from among the various pharmaceutically acceptable additives available to those skilled in the art. These additives include binders, stabilizers, preservatives, flavorings and pigments. In a preferred finite form embodiment, the compositions of the present invention also contain a binder such as lecithin which "binds" the other ingredients, thereby enhancing the uniform consistency of the final composition.

The composition is administered in appropriate sizes, typically having a surface area of from about 0.1 to about 200 cm² or conveniently 0.2 to 100 cm². The anesthetic agent is loaded into the composition in as high a concentration as necessary to effect therapy, e.g., in a range from about 0.1 mg/cm² to about 50 or more mg/cm² or 0.1 mg/ml to about 500 or more mg/ml when a non-finite carrier such as an ointment, gel, lotion, cream, paste, plaster, emulsion, or spray-solution is used.

In general, the composition can have the following types and amounts of ingredients:

Ingredient	Typical	Preferred	Optimum
	Range	Range	Range
	(% by weight)	(% by weight)	(% by weight)
<u>Finite Form</u>			
Adhesive	15 to 60	20 to 50	20 to 35
Solvent (with plast.)	2 to 75	5 to 70	20 to 40
Drug(s)	1 to 50	5 to 40	10 to 30
Clay	0.5 to 20	0.5 to 10	1 to 7

In one embodiment, the flexible, finite, bioadhesive composition for topical application comprises:

a therapeutically effective amount of at least one pharmaceutically active agent;

a pharmaceutically acceptable solvent for the pharmaceutically active agent, including a plasticizer for the bioadhesive, and a cohesiveness increasing amount of clay;

in admixture with the pharmaceutically active agent in the solvent, a pharmaceutically acceptable bioadhesive, preferably a polysaccharide bioadhesive, in an amount from about 20 to about 50 weight percent based on the weight of the whole composition;

wherein the composition is substantially water insoluble and self-adhesive; and wherein the pharmaceutically active agent is present in non-crystallized form in the composition.

The term "administering" is intended to mean any mode of application to a tissue which results in the physical contact of the composition with an anatomical site in need of anesthesia. The term "subject" is intended to include all warm-blooded mammals, preferably humans.

In one method of the invention wherein a bioadhesive carrier is employed, the pharmaceutically acceptable solvent is in a preferred amount from about 20 to about 50 weight percent of which the plasticizer represents

about 10 to 30 weight percent based on the weight of the whole composition, the bioadhesive carrier is in an amount from about 20 to about 50 weight percent and the clay represents about 0.5 to about 20% of the composition based on the weight of the whole composition. More preferably, the bioadhesive composition of this method is comprised of 20 to 40 weight percent of karaya gum, about 20 to 40 weight percent of at least one glycol, and about 10 to 25 weight percent of lidocaine base and 0.5 to 10% of clay, and is further comprised of a binder in an amount sufficient to bind the other ingredients.

In one embodiment, the composition of the invention comprises about 20 to 35 weight percent of karaya gum, about 20 to 40 weight percent of at least one glycol, about 10 to 25 weight percent of lidocaine base, and 1 to 7 percent smectite clay, and further comprising a binder in an amount sufficient to bind the other ingredients.

In another embodiment, the composition of the invention comprises about 10 weight percent of karaya gum, about 13 weight percent of at least one glycol, and about 8 weight percent of lidocaine base, and further comprising a binder in an amount sufficient to bind the other ingredients.

In another embodiment, the composition of the invention comprises about 7 weight percent of karaya gum, about 13 weight percent of at least one glycol, and about 8 weight percent of lidocaine base, and further comprising a binder in an amount sufficient to bind the other ingredients.

In another embodiment, the composition of the invention comprises about 5 weight percent of karaya gum, about 13 weight percent of at least one glycol, and about 8 weight percent of lidocaine base, 2 percent Bentonite, and further comprising a binder in an amount sufficient to bind the other ingredients.

In another embodiment, the composition of the invention comprises about 5 weight percent of karaya gum, about 13 weight percent of at least one glycol, and about

8 weight percent of lidocaine base, 2 percent Bentonite, and further comprising a binder in an amount sufficient to bind the other ingredients.

5 The following examples will further describe the instant invention, and are used for the purposes of illustration only, and should not be considered as limiting in any way the invention being disclosed herein. Percent (%) as used in these examples refer to percentage of the liquid formulation on a weight to weight basis and
10 temperatures are given in degrees celsius (°C).

Example 1

<u>Ingredient</u>		<u>w/w %</u>		
5	Lidocaine base	8.0	8.0	8.0
	8.0			
	Dipropylene Glycol	5.0	5.0	5.0
10	5.0			
	60% Lecithin in			
	Propylene Glycol	8.0	8.0	8.0
15	8.0			
	Karaya Gum	10.0	7.0	5.0
	5.0			
20	Bentonite			
	(Polargel NF*)	0	0	2.0
	2.0			
25	Zinc Oxide	0	0	0
	0.1			
	Glycerin	6.0	6.0	6.0
30	6.0			

20 * Available from American Colloid Co.

25 The final product is manufactured by first blending the lidocaine base, the propylene glycol, lecithin, and glycerin at about 70 to 90°C until all of the drug is dissolved. The solution is then cooled to 20 to 35°C prior to adding the karaya gum and clay. Once the karaya gum and clay is added, the final composition are applied to a suitable backing material such as a non-woven, polyester film (for example, the film sold under the trademark Sontara 8100, manufactured by DuPont de Nemours, E.I. and Co., Wilmington, DE) and warmed to about 100°C to accelerate the formation of the gel into its final, finite form.

35 The foregoing examples are illustrative embodiments of the invention and are merely exemplary. A person skilled in the art may make variations and modification without departing from the spirit and scope of the invention. All such modifications and variations are intended to be included within the scope of the invention as described in this specification and the appended claims.

40 Indeed, the present invention is intended to encompass and be suitable for use by substituting any of

the following drugs for the anesthetic agent as the pharmacologically active agent in the composition and methods for use of the same:

- α -ADRENERGIC AGONIST** such as Adrafinil, Adrenolone,
5 Amidephrine, Apraclonidine, Budralazine, Clonidine, Cyclopentamine, Detomidine, Dimetofrine, Dipivefrin, Ephedrine, Epinephrine, Fenoxazoline, Guanabenz, Guanfacine, Hydroxyamphetamine, Ibopamine, Indanazoline, Isometheptene, Mephentermine, Metaraminol, Methoxamine,
10 Methylhexaneamine, Metizolene, Midodrine, Naphazoline, Norepinephrine, Norfenefrine, Octodrine, Octopamine, Oxymetazoline, Phenylephrine, Phenylpropanolamine, Phenylpropylmethylamine, Pholedrine, Propylhexedrine, Pseudoephedrine, Rilmenidine, Synephrine,
15 Tetrahydrozoline, Tiamenidine, Tramazoline, Tuaminoheptane, Tymazoline, Tyramine, Xylometazoline
 β -ADRENERGIC AGONIST such as Formoterol, Methoxyphenamine, Ritodrine, Terbuterol
 α -ADRENERGIC BLOCKER such as Dapiprazole, Doxazosin,
20 Ergoloid Mesylates, Fenspiride, Prazosin, Terazosin, Tolazoline, Trimazosin, Yohimbine
 β -ADRENERGIC BLOCKER such as Acebutolol, Amosulalol, Arotinolol, Atenolol, Befunolol, Betaxolol, Bevantolol, Bisoprolol, Bopindolol, Bucumolol, Bufetolol, Bufuralol,
25 Bunitrolol, Bupranolol, Butofilolol, Carazolol, Carteolol, Carvedilol, Celiprolol, Cetamolol, Cloranolol, Dilevalol, Epanolol, Esmolol, Indenolol, Labetalol, Levobunolol, Mepindolol, Metipranolol, Metoprolol, Moprolol, Nadolol, Nadoxolol, Nifenalol, Nipradilol,
30 Oxprenolol, Penbutolol, Pindolol, Practolol, Propranolol, Sotalol, Sulfinalol, Talinolol, Tertatolol, Timolol, Toliprolol, Xibenolol
ALCOHOL DETERRENT such as Calcium Cyanamide Citrated, Disulfiram, Nitrefazole
35 **ALDOSE REDUCTASE INHIBITOR** such as Epalrestat, Ponalrestat, Sorbinil, Tolrestat

- ANABOLIC** such as Androisoxazole, Androstenediol, Bolandiol, Bolasterone, Clostebol, Ethylestrenol, Formyldienolone, 4-Hydroxy-19-nortestosterone, Methandriol, Methenolone, 5 Methyltrienolone, Nandrolone, Nandrolone Decanoate, Nandrolone p-Hexyloxyphenyl-propionate, Nandrolone Phenpropionate, Norbolethone, Oxymesterone, Quinbolone, Stenbolone, Trenbolone
- ANALGESIC (DENTAL)** such as Chlorobutanol, Clove, Eugenol, 10 Potassium Nitrate, Potassium Oxalate
- ANALGESIC (NARCOTIC)** such as Alfentanil, Allylprodine, Alphaprodine, Anileridine, Benzylmorphine, Bezitramide, Buprenorphine, Butorphanol, Clonitazene, Codeines, Desomorphine, Dextromoramide, Dezocine, Diampromide, 15 Dihydrocodeine, Dihydrocodeinone Enol Acetate, Dihydromorphine, Dimenoxadol, Dimepheptanol, Dimethylthiambutene, Dioxaphetyl Butyrate, Dipipanone, Eptazocine, Ethoheptazine, Ethylmethlythiambutene, Ethylmorphine, Etonitazene, Fentanyl, Hydrocodone, 20 Hydromorphone, Hydroxypethidine, Isomethadone, Ketobemidone, Levorphanol, Lofentanil, Meperidine, Meptazinol, Metazocine, Methadone, Metopon, Morphine, Morphine Derivatives, Myrophine, Nalbuphine, Narceine, Nicomorphine, Norlevorphanol, Normethadone, Normorphine, 25 Norpipanone, Opium, Oxycodone, Oxymorphone, Papaveretum, Pentazocine, Phenadoxone, Phenazocine, Pheoperidine, Piminodine, Piritramide, Proheptazine, Promedol, Properidine, Propiram, Propoxyphene, Sufentanil, Tilidine
- ANALGESIC (NON-NARCOTIC)** such as Acetaminophen, 30 Acetaminosalol, Acetanilide, Acetylsalicylates, Acetylsalicylsalicylic Acid, Alclofenac, Alminoprofen, Aloxiprin, Aluminum Bis(acetylsalicylate), Aminochlorthenoxazin, 2-Amino-4-picoline, Aminopropylon, Aminopyrine, Antipyrine, Antipyrine Salicylate, 35 Antrafenine, Apazone, Aspirin, Benorylate, Benoxaprofen, Benzpiperylon, Benzydamine, p-Bromoacetanilide, 5-Bromosalicylic Acid Acetate, Bucetin, Bufexamac, Bumadizon, Butacetin, Carbamazepine, Carbetidine,

Carbiphenes, Carsalam, Chloralantipyrine, Chlorthenoxazin(e), Choline Salicylate, Cinchophen, Ciramadol, Clometacin, Cropropamide, Crotethamide, Dexoadrol, Difenamizole, Diflunisal, Dipyracetate, 5 Dipyrone, Emorfazone, Enfenamic Acid, Epirizole, Etersalate, Ethenzamide, Ethoxazene, Etodolac, Felbinac, Fenoprofen, Floctafenine, Flufenamic Acid, Fluoresone, Flupirtine, Fluproquazone, Flurbiprofen, Fosfosal, Gentisic Acid, Glafenine, Ibuprofen, Imidazole Salicylate, 10 Indomethacin, Indoprofen, Isofezolac, Isoladol, Isonixin, Ketoprofen, Ketorolac, p-Lactophenetide, Lefetamine, Loxoprofen, Lysine Acetylsalicylate, Methotrimoprazine, Metofoline, Miroprofen, Morazone, Morpholine Salicylate, Naproxen, Nefopam, Nifenazone, 5' Nitro-2' 15 propoxyacetanilide, Parsalimide, Perisoxal, Phenacetin, Phenazopyridine, Phenocoll, Phenopyrazone, Phenyl Acetylsalicylate, Phenyl Salicylate, Phenylamidol, Pipebuzone, Piperylone, Prodilidine, Propacetamol, Propyphenazone, Proxazole, Quinine Salicylate, 20 Ramifenazone, Rimazolium Metilsulfate, Salacetamide, Salicin, Salicylamide, Salicylamide O-Acetic Acid, Salicylic Acid, Salicylates and Derivatives, Salicylsulfuric Acid, Salsalte, Salverine, Simetidine, Sulfamipyrine, Suprofen, Talniflumate, Tenoxicam, 25 Terofenamate, Tetradrine, Tinoridine, Tolfenamic Acid, Tolpronine, Tramadol, Viminol, Xenbucin, Zomepirac

ANDROGEN such as Boldenone, Fluoxymesterone, Mestanolone, Mesterolone, Methandrostenolone, 17-Methyltestosterone, 17 α -Methyl-testosterone 3-Cyclopentyl Enol Ether, 30 Norethandrolone, Normethandrolone, Oxandrolone, Oxymetholone, Prasterone, Stanlone, Stanozolol, Testosterone, Testosterone 17-Chloral Hemiacetal, Testosterone 17 β -Cypionate, Testosterone Enanthate, Testosterone Nicotinate, Testosterone Pheynylacetate, 35 Testosterone Propionate, Tiomesterone

ANESTHETIC such as Acetamidoeugenol, Alfadolone Acetate, Alfaxalone, Amucaine, Amolanone, Amylocaine, Benoxinate, Betoxycaine, Biphenamine, Bupivacaine, Burethamine,

- Butacaine, Butaben, Butanilicaine, Buthalital,
Butoxycaine, Carticaine,
2-Chloroprocaine, Cocaethylene, Cocaine, Cyclomethycaine,
Dibucaine, Dimethisoquin, Dimethocaine, Dipradon,
5 Dyclonine, Ecgonidine, Ecgonine, Ethyl Aminobenzoate,
Ethyl Chloride, Etidocaine, Etroxadol, β -Eucaine,
Euprocine, Fenalcomine, Fomocaine, Hexobarbital,
Hexylcaine, Hydroxydione, Hydroxyprocaine,
Hydroxytetracaine, Isobutyl p-Aminobenzoate, Kentamine,
10 Leucinocaine Mesylate, Levoradrol, Lidocaine,
Mepivacaine, Meprylcaine, Metabutoxycaine, Methohexital,
Methyl Chloride, Midazolam, Myrtecaine, Naepaine,
Octacaine, Orthocaine, Oxethazaine, Parethoxycaine,
Phenacaine, Phencyclidine, Phenol, Piperocaine,
15 Piridocaine, Polidocanol, Pramoxine, Prilocaine,
Procaine, Propanidid, Propanocaine, Proparacaine,
Propipocaine, Propofol, Propoxycaine, Pseudococaine,
Pyrrocaine, Risocaine, Salicyl Alcohol, Tetracaine,
Thialbarbital, Thimylal, Thiobutabarbital, Thiopental,
20 Tolycaine, Trimecaine, Zolamine
ANOREXIC such as Aminorex, Amphetamine, Benzphetamine,
Chlorphentermine, Clobenzorex, Cloforex, Cyclohexedrine,
Diphenmethoxidine, Fenbutrazate, Fenfluramine,
Fenproporex, Furfurylmethylamphetamine,
25 Levophacetopate, Mefenorex, Metamfetramone,
Norpseudoephedrine, Phenphentermine, Picilorex
ANTHELMINTIC (CESTODES) such as Arecoline, Aspidin,
Aspidinol, Dichlorophen(e), Embelin, Kosin, Naphthalene,
Niclosamide, Pellertierine, Pellertierine Tannate,
30 Quinacrine
ANTHELMINTIC (NEMATODES) such as Alantolactone,
Amoscanate, Ascaridole, Bephenium, Bitoscanate, Carbon
Tetrachloride, Carvacrol, Cyclobendazole,
Diethylcarbamazine, Diphenane, Dithiazanine Iodide,
35 Dymanthine, Gentian Violet, 4-Hexyl-
resorcinol, Kainic Acid, Mebendazole, 2-Naphthol, Oxantel,
Piperazines, Pyrantel, Pyrvinium Pamoate, α -Santonin,
Stilbazium Iodide, Tetrachloroethylene, Thiabendazole,

- Thymol, Thymyl N-Isoamylcarbamate, Triclofenol
Piperazine, Urea Stibamine
- ANTHELMINTIC (ONCHOCERCA)** such as Ivermectin
- ANTHELMINTIC (SCHISTOSOMA)** such as Amphotolide,
5 Antimony(s) and Derivatives, Becanthone, Hycanthone,
Lucanthone, Niridazole, Oxamniquine, Praziquantel,
Stibocaptate, Stibophen
- ANTHELMINTIC (TREMATODES)** such as Anthiolimine
- ANTIACNE** such as Algestone Acetophenide, Azelaic Acid,
10 Benzoyl Peroxide, Dichloroacetic Acid, Motretinide,
Retinoic Acid, Tetroquinone
- ANTIALLERGIC** such as Amlexanox, Astemizole, Azelastine,
Cromolyn, Fenpiprane, Histamines, Ketotifen, Nedocromil,
Oxatomide, Pentigetide, Poison Ivy Extract, Poison Oak
15 Extract, Poison Sumac Extract, Repirinast, Tiaramide,
Tranilast, Traxanox, Urushiol
- ANTIAMEBIC** such as Arsthinol, Bialamicol, Carbarsone,
Cephaeline, Chlorbetamide, Chlorphenoxamide,
Dehydroemetine, Dibromopropamidine, Diloxanide,
20 Dephetarsone, Emetine, Fumagillin, Glaucarubin,
Glycobiarsol, 8-Hydroxy-7-iodo-5-quinolinesulfonic Acid,
Iodochlorhydroxyquin, Iodoquinol, Paromomycin,
Phanquinone, Phearsone Sulfoxylate, Polybenzarsol,
Propamidine, Quinfamide, Secnidazole, Sulfarside,
25 Teclozan, Thiocarbamazine, Thiocarbarsone, Tinidazole
- ANTIANDROGEN** such as Bifluranol, Cyoctol, Cyproterone,
Oxendolone
- ANTIANGINAL** such as Amlodipine, Amyl Nitrite, Cinepazet
Maleate, Imolamine, Isosorbide Dinitrate, Limaprost,
30 Molsidomine, Nitroxyalklamide Derivatives
- ANTIARRHYTHMIC** such as Acecaine, Adenosine, Ajmaline,
Alprenolol, s-Aminoalkyl-s-Arylsulfoximines, Amoproxan,
Aprindine, Bretylium Tosylate, Bubumolol, Bunaftine,
Butidrine, Butobendine, Capobenic Acid, Cifenline,
35 Disopyramide, Encainide, Flecainide, Hydroquinidine,
Indecainide, Ipratropium, Lorajmine, Lorcainide,
Meobentine, Mexiletine, Moricizine, Pirmenol, Prajmaline,
Procainamide, Pronethalol, Propafenone, Pyrinoline,

Quinidine, Quinidine Sulfate, Quinidine, Tocainide, Viqualidil

ANTIARTERIOSCLEROTIC such as Pyridinol Carbamate

ANTIARTHRITIC/ANTIRHEUMATIC such as Allocupreide Sodium, Auranofin, Aurothioglucose, Aurothioglycanide, Azathioprine,

Di-tert-Butylphenols, Calcium 3-Aurothio-2-propanol-1-sulfonate, Clobuzarit, Cuproxoline, Diacerein, Glucosamine, Gold Sodium Thiomalate, Gold Sodium Thiosulfate, Hydroxychloroquine, Kebuzone, Lobenzarit, Melittin, Myoral, Penicillamine

ANTIBACTERIAL (ANTIBIOTIC)

Aminoglycosides such as Amikacin, Apramycin, Arbekacin, Bambermycins, Butirosin, Dibekacin, Dihydrostreptomycin, Fortimicin(s), Fradiomycin, Gentamicin, Ispamicin, Kanamycin, Micronomicin, Neomycin, Neomycin Undecylenate, Netilmicin, Paromomycin, Ribostamycin, Sisomicin, Spectinomycin, Streptomycin, Streptonicozid, Tobramycin

Amphenicols such as Azidamfenicol, Chloramphenicol, Chloramphenicol Palmitate, Chloramphenicol Pantothenate, Florfenicol, Thiamphenicol

Ansamycins such as Rifamide, Rifampin, Rifamycin, Rifaximin

β -Lactams

Carbapenems such as Imipenem

Cephalosporins such as 1-Carba (dethia)

Cephalosporin, Cefactor, Cefadroxil, Cefamandole, Cefatrizine, Cefazedone,

Cefazolin, Cefixime, Cefmenoxime, Cefodizime, Cefonicid, Cefoperazone, Ceforanide, Cefotaxime, Cefotiam, Cefpimizole, Cefpirimide, Cefpodoxime Proxetil, Cefroxadine, Cefsulodin, Ceftazidime, Cefteram, Ceftezole, Ceftibuten, Ceftizoxime, Ceftriaxone,

Cefuroxime, Cefuzonam, Cephacetrile Sodium, Cephalixin, Cephaloglycin, Cephaloridine, Cephalosporin, Cephalothin, Cephapirin Sodium, Cephradine, Pivcefalexin

Cephameycins such as Cefbuperazone, Cefmetazole, Cefminox, Cefetan, Cefoxitin

Monobactams such as Aztreonam, Carumonam, Tigemonam

5 Oxacephems such as Flomoxef, Moxolactam

Penicillins such as Amidinocillin, Amdinocillin
Pivoxil, Amoxicillin, Ampicillin, Apalcillin,
Aspoxicillin, Azidocillin, Azlocillin, Bacampicillin,
Benzylpenicillinic Acid, Benzylpenicillin, Carbenicillin,
10 Carfecillin, Carindacillin, Clometocillin, Cloxacillin,
Cyclacillin, Dicloxacillin, Diphenicillin, Epicillin,
Fenbenicillin, Floxicillin, Hetacillin, Lenampicillin,
Metampicillin, Methicillin, Mezlocillin, Nafcillin,
Oxacillin, Penamecillin, Penethamate Hydriodide,
15 Penicillin G Benethamine, Penicillin G Benzathine,
Penicillin G Benzhydrylamine, Penicillin G Calcium,
Penicillin G Hydrabamine, Penicillin G Potassium,
Penicillin G Procaine, Penicillin N, Penicillin O,
Penicillin V, Penicillin V Benzathine, Penicillin V
20 Hydrabamine, Penimepicycline, Phenethicillin,
Piperacillin, Pivapicillin, Propicillin, Quinacillin,
Sulbenicillin, Talampicillin, Temocillin, Ticarcillin

Lincosamides such as Clindamycin, Lincomycin

Macrolides such as Azithromycin, Carbomycin,
25 Clarithromycin, Erythromycin(s) and Derivatives,
Josamycin, Leucomycins, Midecamycins, Miokamycin,
Oleandomycin, Primycin, Rokitamycin, Rosaramicin,
Roxithromycin, Spiramycin, Troleandomycin

Polypeptides such as Amphomycin, Bacitracin,
30 Capreomycin, Colistin, Enduracidin, Enviomycin,
Fusafungine, Gramicidin(s), Gramicidin S, Mikamycin,
Polymyxin, Polymyxin B-Methanesulfonic Acid,
Pristinamycin, Ristocetin, Teicoplanin, Thiostrepton,
Tuberactinomycin, Tyrocidine, Tyrothricin, Vancomycin,
35 Viomycin(s), Virginiamycin, Zinc Bacitracin

Tetracyclines such as Apicycline, Chlortetracycline,
Clomocycline, Demeclocycline, Doxycycline, Guamecycline,
Lymecycline, Meclocycline, Methacycline, Minocycline,

Oxytetracycline, Penimepicycline, Pipacycline,
Rolitetracycline, Sancycline, Senociclin, Tetracycline

Others such as Cycloserine, Mupirocin, Tuberin,

ANTIBACTERIAL (SYNTHETIC)

- 5 **2,4-Diaminopyrimidines** such as Brodimoprim,
Tetroxoprim, Trimethoprim
- Nitrofurans** such as Furaltadone, Furazolium,
Nifuradene, Nifuratel, Nifurfoline, Nifurpirinol,
Nifurprazine, Nifurtoinol, Nitrofurantoin
- 10 **Quinolones and Analogs** such as Amifloxacin,
Cinoxacin, Ciprofloxacin, Difloxacin, Enoxacin,
Fleroxacin, Flumequine, Lomefloxacin, Miloxacin,
Nalidixic Acid, Norfloxacin, Ofloxacin, Oxolinic Acid,
Pefloxacin, Pipemidic Acid, Piromidic Acid, Rosoxacin,
15 Temafloxacin, Tosufloxacin
- Sulfonamides** such as Acetyl Sulfamethoxypyrazine,
Acetyl Sulfisoxazole, Azosulfamide, Benzylsulfamide,
Chloramine-B, Chloramine-T, Dichloramine T,
Formosulfathiazole, *N*²-Formyl-
- 20 sulfisomidine, *N*⁴- β -D-Glucosylsulfanilamide, Mafenide,
4'-(Methyl-sulfamoyl)sulfanilamide, *p*-
Nitrosulfathiazole, Noprylsulfamide,
Phthalylsulfacetamide, Phthalylsulfathiazole,
Salazosulfadimidine, Succinylsulfathiazole,
- 25 Sulfabenzamide, Sulfacetamide, Sulfachlorpyridazine,
Sulfachrysoidine, Sulfacytine, Sulfadiazine,
Sulfadicramide, Sulfadimethoxine, Sulfadoxine,
Sulfaethidole, Sulfaguanidine, Sulfaguanol, Sulfalene,
Sulfaloxic Acid, Sulfamerazine, Sulfameter,
- 30 Sulfamethazine, Sulfamethizole, Sulfamethomidine,
Sulfamethoxazole, Sulfamethoxypyridazine, Sulfametrole,
Sulfamidochrysoidine, Sulfamoxole, Sulfanilamide,
Sulfanilamidomethanesulfonic Acid Triethanolamine Salt,
- 4-Sulfanilamidosalicylic Acid, *N*⁴-
- 35 Sulfanilylsulfanilamide, Sulfanilylurea, *N*-Sulfanilyl-
3,4-xylamide, Sulfanitran, Sulfaperine, Sulfaphenazole,
Sulfaproxyline, Sulfapyrazine, Sulfapyridine,
Sulfasomizole, Sulfasymazine, Sulfathiazole,

Sulfathiourea, Sulfatolamide, Sulfisomidine,
Sulfisoxazole

5 **Sulfones** such as Acedapsone, Acediasulfone,
Acetosulfone, Dapsone, Diathymosulfone, Glucosulfone,
Solasulfone, Succisulfone, Sulfanilic Acid, p-
Sulfanilylbenzylamine, p,p'-Sulfonyldianiline-N,N'
digalactoside, Sulfoxone, Thiazolsulfone

10 **Others** such as Clofocetol, Hexedine, Magainins,
Methenamine, Methenamine Anhydromethylene-citrate,
Methenamine Hippurate, Methenamine Mandelate, Methenamine
Sulfosalicylate, Nitroxoline, Squalamine, Xibornol

ANTICHOLINERGIC such as Adiphenine, Alverine,
Ambutonium, Aminopentamide, Amixetrine, Amprotropine
Phosphate, Anisotropine Methylbromide, Apotatropine,
15 Atropine, Atropine N-Oxide, Benactyzine, Benapryzine,
Benzetimide, Benzilonium, Benztropine Mesylate, Bevonium
Methyl Sulfate, Biperiden, Butropium, N-
Butylscopolammonium Bromide, Buzepide, Camylofine,
Caramiphen, Chlorbenzoxamine, Chlorphenoxamine,
20 Cimetropium, Clidinium, Cyclo-drine, Cyclonium,
Cyclopentolate, Cycrimine, Deptropine, Dexetimide,
Dibutoline Sulfate, Dicyclomine, Diethazine, Difemerine,
Dihexyverine, Diphemaniol Methylsulfate, N-(1,2-
Diphenylethyl)nicotinamide, Dipipraverine, Diponium,
25 Emepromium, Endobenzylamine, Ethopropazine,
Ethybenztropine, Ethylbenzhydramine, Etomidoline,
Eucatropine, Fempiverinium, Fentonium, Flutropium,
Glycopyrrolate, Heteronium, Hexocyclium Methyl Sulfate,
Homatropine, Homatropine Methyl Bromide, Hyoscyamine,
30 Ipratropium, Isopropamide, Levomepate, Meclozamine,
Mepenzolate, Metcaraphen, Methantheline, Methixene,
Methscopolamine, Octamylamine, Oxybutynin,
Oxyphencyclimine, Oxyphenonium, Pentapiperide,
Penthienate, Phencarbamide, Phenglutarimide, Pipenzolate,
35 Piperidolate, Piperilate, Poldine Methysulfate, Pridinol,
Prifinium, Procyclidine, Propantheline, Propenzolate,
Propyromazine, Scopolamine N-Oxide, Stilonium,
Stramonium, Sultroponium, Thihexinol, Thiphenamil,

Tiemonium, Timepidium, Tiquizium, Tridihexethyl Iodide, Trihexyphenidyl Hydrochloride, Tropacine, Tropenzile, Tropicamide, Trospium, Valethamate, Xenytropium

ANTICONVULSANT such as Acetylpheneturide, Albutoin,

- 5 Aloxidone, Aminoglutethimide, 4-Amino-3-hydroxybutyric Acid, Atrolactamide, Beclamide, Buramate, Carbamazepine, Cinromide, Clonazepam, Decimemide, Diethadione, Dimethadione, Doxenitoin, Eterobarb, Ethadione, Ethosuximide, Ethotoin, Fluoresone, 5-
10 Hydroxytryptophan, Lamotrigine, Magnesium Sulfate, Mephenytoin, Metharbital, Methetoin, Methsuximide, 5-Methyl-5-(3-phenanthryl)-hydantoin, 3-Methyl-5-phenylhydantoin, Narcobarbital, Nimetazepam, Nitrazepam, Paramethadione, Phenacemide, Pheneturide, Phensuximide,
15 Phenytoin, Phethenylate Sodium, Primidone, Progabide, Solanum, Strontium, Suclofenide, Sulthiame, Tetrantoin, Trimethadione, Valproic Acid, Valpromide, Vigabatrin, Zonisamide

ANTIDEPRESSANT

- 20 **Bicyclics** such as Binedaline, Caroxazone, Citalopram, Dimethazan, Indalpine, Fencamine, Indeloxazine, Nefopam, Nomifensine, Oxitriptan, Oxypertine, Paroxetine, Sertraline, Thiazesim, Trazodone, Zometapine

- Hydrazides/Hydrazines** such as Benmoxine, Iproclozide,
25 Iproniazid, Isocarboxazid, Nialamide, Octamoxin, Phenelzine

Pyrrolidones such as Cotinine, Rolicyprine, Rolipram

Tetracyclics such as Maprotiline, Metralindole, Mianserin, Oxaprotiline

- 30 **Tricyclics** such as Adinazolam, Amitriptyline, Amitriptylinoxide, Amoxapine, Butriptyline, Clomipramine, Demexiptiline, Desipramine, Dibenzepin, Dimetracrine, Dothiepin, Doxepin, Fluacizine, Imipramine, Imipramine N-Oxide, Iprindole, Lofepramine, Melitracen, Metapramine,
35 Nortriptyline, Noxiptilin, Opipramol, Propizepine, Protriptyline, Quinupramine, Tianeptine, Trimipramine

Others such as Benactyzine, Bupropion, Butacetin, Deanol, Deanol Aceglumate, Deanol Acetamidobenzoate,

Dioxadrol, Etoferidone, Febarbamate, Femoxetine, Fenpentadiol, Fluoxetine, Fluvoxamine, Hematoporphyrin, Hypercinin, Levophacetoperane, Lithium, Medifoxamine, Minaprine, Moclobemide, Oxaflozane, Piberaline, 5 Polycyclic Imides, Prolintane, Pyrisuccideanol, Rubidium, Sulpiride, Sultopride, Teniloxazine, Thozalinone, Tofenacin, Toloxatone, Tranlycypromine, L-Tryptophan, Viloxazine, Zimeldine

ANTIDIABETIC

10 **Biguanides** such as Buformin, Metformin, Phenformin
Sulfonylurea Derivatives such as Acetohexamide, 1-Butyl-3-metanilylurea, Carbutamide, Chlorpropamide, Glibornuride, Gliclazide, Glimepiride, Glipizide, Gliquidone, Glisoxepid, Glyburide, Glybuthiazol(e), 15 Glybuzole, Glyhexamide, Glymidine, Glypinamide, Phenbutamide, Tolazamide, Tolbutamide, Tolcyclamide

Others such as Acarbose, Benzylthiazolidene-2,4-dione, Calcium Mesoxalate, Miglitol

ANTIDIARRHEAL such as Acetyltannic Acid, Albumin Tannate, 20 Alkofanone, Aluminum Salicylates, Catechin, Difenoxin, Diphenoxylate, Lidamidine, Loperamide, Mebiquine, Trillium, Uzarin

ANTIDIURETIC such as Desmopressin, Felypressin, Lypressin, Ornipressin, Oxycinchophen, Terlipressin, 25 Vasopressin

ANTIESTROGEN such as Delmadinone Acetate, Ethamoxytriphethol, Tamoxifen, Toremifene

ANTIFUNGAL (ANTIBIOTICS)

Polyenes such as Amphotericin-B, Candicidin, 30 Dermostatin, Filipin, Fungichromin, Hachimycin, Hamycin, Lucensomycin, Mepartricin, Natamycin, Nystatin, Pecilocin, Perimycin

Others such as Azaserine, Griseofulvin, Oligomycins, Pyrrolnitrin, Siccanin, Tubercidin, Viridin

35 **ANTIFUNGAL (SYNTHETIC)**

Allylamines such as Naftifine, Terbinafine

Imidazoles such as Bifonazole, Butoconazole, Chlordantoin, Chlormidazole, Cloconazole, Clotrimazole,

Econazole, Enilconazole, Fenticonazole, Isoconazole,
Ketoconazole, Miconazole, Omoconazole, Oxiconazole
Nitrate, Sulconazole, Tioconazole

5 **Triazoles** such as Fluconazole, Itraconazole,
Terconazole

Others such as Acrisorcin, Amorolfine, Biphenamine,
Bromosalicylchloranilide, Buclosamide, Chlophenesin,
Ciclopirox, Cloxyquin, Coparaffinate, Diamthazole,
Dihydrochloride, Exalamide, Flucytosine, Halethazole,
10 Hexetidine, Loflucarban, Nifuratel, Potassium Iodide,
Propionates, Propionic Acid, Pyrithione, Salicylanilide,
Sulbentine, Tenonitroazole, Tolciclate, Tolindate,
Tolnaftate, Tricetin, Ujothion, Undecylenic Acid

ANTI GLAUCOMA such as Dapiprazole, Dichlorphenamide,
15 Dipivefrin, Pilocarpine

ANTIGONADOTROPIN such as Danazol, Gestrinone,
Paroxypropione

ANTIGOUT such as Colchicine, Probenecid, Sulfapyrazole
ANTI HISTAMINIC

20 **Alkylamine Derivatives** such as Acrivastine, Bamipine,
Brompheniramine, Chlorpheniramine, Dimethindene, Metron
S, Pheniramine, Pyrrobutamine, Thenaldine, Tolpropamine,
Triprolidine

Aminoalkyl Ethers such as Bietanautine,
25 Bromodiphenhydramine, Carbinoxamine, Clemastine,
Diphenylpyraline, Doxylamine, Embrammine, Medrylamine,
Mephenphedramine, p-Methyldiphenhydramine, Orphenadrine,
Phenyltoloxamine, Piprinhydrinate, Setasine

Ethylenediamine Derivatives such as Alloclamide,
30 p-Bromtripelennamine, Chloropyramine, Chlorothene,
Histapyrrodine, Methafurylene, Methaphenylene,
Methapyrilene, Phenbenzamine, Pyrilamine, Talastine,
Thenyldiamine, Thonzylamine, Tripelennamine, Zolamine

Piperazines such as Cetirizine, Chlorcyclizine,
35 Clocinazine, Hydroxyzine

Tricyclics

Phenothiazines such as Ahistan, Etymemazine,
Fenethazine, N-Hydroxyethylpromethazine, Isopromethazine,

Mequitazine, Promethazine, Pyrathiazine, Thiazinamium Methyl Sulfate

Others such as Azatadine, Cllobenzepam, Cyproheptadine, Deptropine, Isothipendyl, Loratadine, Prothipendyl

Others such as Antazoline, Cetoxime, Clemizole, Cllobenztropine, Diphenazoline, Diphenhydramine, Mebhydroline, Phenindamine, Terfenadine, Tritoqualine

ANTIHYPERLIPOPROTEINEMIC

Aryloxyalkanoic Acid Derivatives such as Beclorbrate, Bazafibrate, Binifibrate, Ciprofibrate, Clinofibrate, Clofibrate, Clofibric Acid, Etonfibrate, Fenofibrate, Gemfibrozil, Nicofibrate, Pirifibrate, Ronifibrate, Simfibrate, Theofibrate

Bile Acid Sequesterants such as Cholestyramine Resin, Colestipol, Polidexide

HMG CoA Reductase Inhibitors such as Lovastatin, Pravastatin, Simvastatin

Nicotinic Acid Derivatives Aluminum Nicotinate, Acipimox, Niceritrol, Nicoclonate, Nicomol, Oxiniacic Acid

Thyroid Hormones/Analogues such as Etiroxate, Thyropropic Acid

Others such as Acifran, Azacosterol, Benfluorex, β -Benzalbutyramide, Benzodioxole, Carnitine, Chondroitin Sulfate, Clomestone, Detaxtran, Dextran Sulfate Sodium, 5,8,11,14,17-Eicosapentaenoic Acid, Eritadenine, Farnesylated tetrahydro-naphthalenols, Furazbol, Meglutol, Melinamide, Mytatrienediol, Naphtyl-tetrahydronaphtyl-diphosphonates, Ornithine, γ -Oryzanol, Pantethine, Penataerythritol Tetraacetate, α -Phenylbutyramide, Phylate Acids and Salts, Pirozadil, Probucol, α -Sitosterol, Sultosilic Acid, Tiadenol, Triparanol

ANTIHYPERTENSIVE

Benzothiadiazine Derivatives such as Althiazide, Bendroflumethiazide, Benzthiazide, Benzylhydrochlorothiazide, Buthiazide, Chlorothiazide, Chlorthalidone, Cyclopenthiazide, Cyclothiazide,

- Diazoxide, Epithiazide, Ethiazide, Fenquizone,
Hydrochlorothiazide, Hydroflumethiazide,
Methyclothiazide, Meticrane, Metolazone, Paraflutizide,
Polythiazide, Tetrachlormethiazide, Trichlormethiazide
- 5 **N-Carboxyalkyl (peptide/lactam) Derivatives** such as
Alacepril, Captopril, Cilazapril, Delapril, Enalapril,
Enalaprilat, Fosinopril, Lisinopril, Moveltipril,
Perindopril, Quinapril, Ramipril
- 10 **Guanidine Derivatives** Bethanidine, Debrisoquin,
Guanaciline, Guanadrel, Guanazodine, Guanethidine,
Guanochlor, Guanoxabenz, Guanoxan
- Hydrazines/Phthalazines** such as Cadralazine,
Dihydralazine, Endralazine, Hydracarbazine, Hydralazine,
Pheniprazine, Pildralazine, Todralazine
- 15 **Imidazole Derivatives** such as Lofexidine,
Phentolamine, Tolonidine
- Quaternary Ammonium Compounds** Azamethonium,
Chlorisondamine, Hexamethonium, Pentacynium Bis(methyl
sulfate), Pentamethonium, Pentolinium Tartate,
20 Phenactopinium, Trimethidionum Methosulfate
- Quinazoline Derivatives** such as Alfuzosin, Bunazosin
- Reserpine Derivatives** such as Bietaserpine,
Deserpidine, Rescinamine, Reserpine, Syrosingopine

Sulfonamide Derivatives such as Ambuside, Clopamide, Furosemide, Indapamide, Quinethazone, Tripamide, Xipamide

Others such as Ajmaline, γ -Aminobutyric Acid, Bufeniode, Chlorthalidone, Cicletaine, Ciclosidomine, 5 Cryptenamine Tannates, Flosequinan, Indoramin, Ketanserine, Metbutamate, Mecamylamine, Methyldopa, Methyl 4-Pyridyl Ketone Thiosemicarbarzone, Metolazone, Minoxidil, Muzolimine, Pargyline, Pempidine, Pinacidil, Piperoxan, Primaperone, Propargyl Glycine Aminopropargyl 10 Diols, Protoveratrines, Raubasine, Rescimetol, Saralasin, Sodium Nitroprusside, Ticrynafene, Trimethaphan Camsylate, Tyrosinase, Urapidil

ANTIHYPERTHYROID such as 2-Amino-4-methylthiazole, 2-Aminothiazole, Carbimazole, 3,5-Dibromo-L-tyrosine, 15 3,5-Diiodotyrosine, Hinderin, Iodine, Iothiouracil, Methimazole, Methylthiouracil, Propylthiouracil, Sodium Perchlorate, Thibenzazoline, Thiobarbital, 2-Thiouracil

ANTIHYPOTENSIVE such as Amezinium Methyl Sulfate, Angiotensin Amide, Etifelmin, Etilefrin, Gepefrine

20 **ANTIHYPOTHYROID** such as Levothyroxine, Liothyronine, Thyroid, Thyroidin, Thyroxine, Tiratricol

ANTI-INFLAMMATORY (NONSTEROIDAL)

Aminoarylcarboxylic Acid Derivatives such as Etofenamate, Meclofenamic Acid, Mefenamic Acid, Niflumic 25 Acid

Arylacetic Acid Derivatives such as Acemetacin, Amfenac, Cinmetacin, Clopirac, Diclofenac, Fenclofenac, Fenclozic Acid, Fentiazac, Glucametacin, Isoxepac, Lonazolac, Metiazinic Acid, Oxametacine, 30 Proglumetacin, Sulindac, Tiaramide, Tolmetin

Arylbutyric Acid Derivatives such as Butibufen, Fenbufen

Arylcarboxylic Acids such as Clidanac, Ketorolac, Tinoridine

35 **Arylpropionic Acid Derivatives** such as Bucloxic Acid, Carprofen, Fenoprofen, Flunoxaprofen, Ibuprofen, Ibuprofen, Oxaprozin, Piroxicam, Piroxicam, Pirprofen, Pranoprofen, Protizinic Acid, Tiaprofenic Acid

Pyrazoles such as Mepirizole

Pyrazolones such as Clofezone, Feprazone, Mofebutazone, Oxyphenbutazone, Phenylbutazone, Phenyl Pyrazolidininones, Suxibuzone, Thiazolinobutazone

- 5 **Salicylic Acid Derivatives** such as Bromosaligenin, Fendosal, Glycol Salicylate, Mesalamine, 1-Naphthyl Salicylate, Olsalazine, Sulfasalazine

Thiazinecarboxamides such as Droxicam, Isoxicam, Piroxicam

- 10 **Others** such as ϵ -Acetamidocaproic Acid, S-Adenosyl-methionine, 3-Amino-4-hydroxybutyric Acid, Amixetrine, Bendazac, Bucolome, Carbazones, Difenpiramide, Ditazol, Guaiazulene, Heterocyclic Aminoalkyl Esters of Mycophenolic Acid and Derivatives, Nabumetone, 15 Nimesulide, Orgotein, Oxaceprol, Oxazole Derivatives, Paranyline, Pifoxime, 2-substituted-4, 6-di-tertiary-butyl-s-hydroxy-1,3-pyrimidines, Proquazone, Sialyl Lewis^x Dimers, Tenidap

- ANTIMALARIAL** such as Acedapsone, Alphaaminoquinolines, 20 4-Aminoquinolines, Amodiaquin, Arteether, Artemether, Artemisinin, Artesunate, Bebeerine, Berberine, Chirata, Chlorguanide, Chloroquine, Chlorproguanil, Cinchona, Cinchonidine, Cinchonine, Cycloguanil, Euquinine, Gentiopicroin, Halofantrine, Mefloquine Hydrochloride, 3- 25 Methylarsacetin, Pamaquine, Plasmocid, Primaquine, Pyrimethamine, Quinacrine, Quinine (Acids, Salts and Derivatives), Quinine Formate, Quinine Gluconate, Quinine Tannate, Quinine Urea Hydrochloride, Quinocide, Quinoform, Quinoline, Sodium Arsenate, Diabasic

- 30 **ANTIMIGRAINE** such as Alpiropride, Dihydroergotamine, Ergocornine, Ergocorninine, Ergocryptine, Ergot, Ergotamine, Flumedroxone Acetate, Fonazine, Methysergid(e), Oxetorone, Pizotyline, Sumatriptan

- ANTINAUSEANT** such as Acetylleucine Monoethanolamine, 35 Bietanautine, Bromopride, Buclizine, Clebopride, Cyclizine, Dimenhydrinate, Dipheniodol, Domperidone, Granisetron, Meclizine, Methalltal, Metoclopramide, Metopimazine, Nabilone, Ondansteron, Oxypendyl,

Pipamazine, Piprinhydrinate, Scopolamine,
Tetrahydrocannabinols, Thiethylperazine,
Trimethobenzamide

ANTINEOPLASTIC

5 **Alkylating agents**

Alkyl Sulfonates such as Busulfan, Improsulfan,
Piposulfan

Aziridines such as Benzodepa, Carboquone,
Meturedopa, Uredopa

10 *Ethylenimines and Methylmelamines* such as
Altretamine, Triethylenemelamine,
Triethylenephosphoramidate, Triethylenethiophosphoramidate,
Trimethylolomelamine

Nitrogen Mustards such as Chlorambucil,
15 Chlornaphazine, Chclophosphamide, Estramustine,
Ifosfamide, Mechlorethamine, Mechlorethamine Oxide
Hydrochloride, Melphalan, Novembichin, Phenesterine,
Prednimustine, Trofosfamide, Uracil Mustard

Nitrosoureas Carmustine, Chlorozotocin,
20 Fotemustine, Lomustine, Nimustine, Ranimustine

Others such as Dacarbazine, Mannomustine,
Mitobronitol, Mitolactol, Pipobroman

Antibiotics such as Aclacinomycins, Actinomycin F₁,
Anthracycline, Azaserine, Bleomycins, Cactinomycin,
25 Carubicin, Carzinophilin, Chromomycins, Dactinomycin,
Daunorubicin,

6-Diazo-5-oxo-L-norleucine, Doxorubicin, Epirubicin,
Mitomycins, Mycophenolic Acid, Nogalamycin, Olivomycins,
Peplomycin, Plicamycin, Porfiromycin, Puromycin,
30 Streptonigrin, Streptozocin, Tubercidin, Ubenimex,
Zinostatin, Zorubicin

Antimetabolites

Folic Acid Analogs such as Denopterin,
Methotrexate, Pteropterin, Trimetrexate

35 *Purine Analogs* such as Fludarabine, 6-
Mercaptopurine, Thiamiprine, Thioguanine

Pyrimidine Analogs such as Ancitabine,
Azacitidine, 6-Azauridine, Carmofur, Cytarabine,

Dideoxyuridines, Doxifluridine, Enocitabine, Floxuridine, Fluororacil, Tegafur

Enzymes such as L-Asparaginase, Pulmozyme

Others such as Aceglatone, Aldophosphamide Glycoside,
5 Aminolevulinic Acid, Amsacrine, Bestrabucil, Bisantrone,
Carboplatin, Cisplatin, Defofamide, Demecolcine,
Diaziquone, Elfornithine, Elliptinium Acetate, Etoglucid,
Etoposide, Gallium Nitrate, Hydroxyurea, Interferon- α ,
Interferon- β , Interferon- γ , Interleukine-2, Lentinan,
10 Lonidamine, Mitoguazone, Mitoxantrone, Mopidamol,
Nitracrine, Pentostatin, Phenamet, Pirarubicin,
Podophyllinicc Acid, 2-Ethythydrazide, Procarbazine,
PSK[®], Razoxane, Sizofiran, Spirogermanium, Taxol,
Teniposide, Tenuazonic Acid, Triaziquone, 2,2',2"-
15 Trichlorotriethylamine, Urethan, Vinblastine,
Vincristine, Vindesine

ANTINEOPLASTIC (HORMONAL)

Androgens such as Calusterone, Dromostanolone
Propionate, Epitiostanol, Mepitiostane, Testolactone

20 **Antiadrenals** such as Aminoglutethimide, Mitotane,
Trilostane

Antiandrogens such as Flutamide, Nilutamide

Antiestrogens such as Aromatase Inhibiting 4(5)-
Imidazoles

25 **ANTINEOPLASTIC ADJUNCT**

Folic Acid Replenisher such as Frolinic Acid

ANTIPARKINSONIAN such as Amantadine, Benserazide,
Bietanautine, Biperiden, Budipine, Carbidopa, Deprenyl,
Dexetimide, Diethazine, Droxidopa, Ethopropazine,
30 Ethylbenzhydramine, Levodopa, Piroheptine, Pridinol,
Prodipine, Terguride, Tiapride, Tigloidine

ANTIPHEOCHROMOCYTOMA such as Metyrosine, Phenoxybenzamine

ANTIPNEUMOCYSTIS such as Effornithine

ANTIPROSTATIC HYPERTROPHY such as Proscar[®]

35 **ANTIPROTOZOAL (LEISHMANIA)** such as Ethylstibamine,
Hydroxystilbamidine, N-Methylglucamine, Pentamidine,
Stilbamidine

- ANTIPROTOZOAL (TRICHOMONAS)** such as Acetarsone, Aminitrozole, Anisomycin, Azanidazole, Forminitrazole, Furazolidone, Hachimycin, Lauroguadine, Metronidazole, Nifuratel, Nimorazole, Silver Picrate, Tenonitrozole
- 5 **ANTIPROTOZOAL (TRYPANOSOMA)** such as Benznidazole, Eflornithine, Melarsoprol, Nifurtimox, Oxophenarsine, Puromycin, Quinapyramine, Suramin Sodium, Trypan Red, Tryparasme
- ANTIPRURITIC** such as Camphor, Cyproheptadine,
- 10 Dichlorisone, Glycine, Halometasone, 3-Hydroxycamphor, Menthol, Mesulphen, Methdilazine, Phenol, Spirit of Camphor, Trimeprazine
- ANTIPSORIATIC** such as Acitretin, Anthralin, 6-Azaauridine, Bergapten(e), Chrysarobin, Etretinate, Pyrogallol
- 15 **ANTIPSYCHOTIC**
- Butyrophenones** such as Benperidol, Bromperidol, Droperidol, Fluanisone, Haloperidol, Melperone, Moperone, Pipamperone, Sniperone, Timiperone, Trifluoperidol

- Phenothiazines** such as Acetophenazine, Butaperazine, Carphenazine, Chlorproethazine, Chlorpromazine, Clospirazine, Cyamemazine, Dixyrazine, Fluphenazine, Imiclopazine, Mepazine, Mesoridazine, Methoxypromazine, Metofenazate, Oxaflumazine, Perazine, Pericyazine, Perimethazine, Perphenazine, Piperacetazine, Pipotiazine, Prochlorperazine, Promazine, Sulforidazine, Thiopropazate, Thioridazine, Trifluoperazine, Triflupromazine
- Thioxanthenes** such as Chlorprothixene, Clopenthixol, Flupentixol, Thiothixene
- Other Tricyclics** such as Benzquinamide, Carpipramine, Clocapramine, Clomacran, Clothiapine, Clozapine, Opipramol, Prothipendyl, Tetrabenazine, Zotepine
- Others** such as Alizapride, Amisulpride, 4-Arylpiperazines, 4-Arylpiperdines, Buramate, Fluspirilene, Molindone, Penfluridol, Pimozide, Spirilene, Sulpiride
- ANTIPYRETIC** such as Aconine, Aconite, Aconitine, Phenicarbazide
- ANTIRICKETTSIAL** such as p-Aminobenzoic Acid
- ANTISEBORRHEIC** such as 3-O-Lauroylpyridoxol Diacetate, Piroctone, Resorcinol, Selenium Sulfides, Tioxolone
- ANTISEPTIC**
- Guanidines** such as Alexidine, Ambazone, Chlorhexidine, Picloxydine
- Halogens/Halogen Compounds** such as Bornyl Chloride, Calcium Iodate, Iodine, Iodine Monochloride, Iodine Trichloride, Iodoform, Povidone-Iodine, Sodium Hypochlorite, Sodium Iodate, Symclosene, Thymol Iodide, Triclocarban, Triclosan, Troclosene Potassium
- Nitrofurans** such as Furazolidone, 2-(Methoxymethyl)-5-Nitrofuran, Nidroxyzone, Nifuroxime, Nifurzide, Nitrofurazone
- Phenols** such as Acetomerocetol, Chloroxylenol, Hexachlorophene, 1-Naphthyl Salicylate, 2,4,6-Tribromo-m-cresol, 3',4',5-Trichloro-salicylanilide

Quinolines such as Aminoquinuride, Chloroxine, Chlorquinaldol, Cloxyquin, Ethylhydrocupreine, Halquinol, Hydrastine, 8-Hydroxquinoline Sulfate

Others such as Boric Acid, Chloroazodin, *m*-Cresyl
5 Acetate, Cupric Sulfate, Ichthammol

ANTISPASMODIC such as Alibendol, Ambucetamide, Aminopromazine, Bietamiverine, Butaverine, Butropium, Caroverine, Cimetropium, Cinnamedrine, Clebopride, Coniine Hydrobromide, Coniine, Difemerine, Diisopromine,
10 Dioxaphetyl Butyrate, Drofenine, Ethaverine, Feclemine, Fenalamide, Fenoverine, Fenpiprane, Flavoxate, Flopropione, Gluconic Acid, Guaiactamine, Hydramitrazine, Hymecromone, Leiopyrrole, Mebeverine, Moxaverine, Nafiverine, Octaverine, Phenamacide, Phloroglucinol,
15 Pinaverium, Piperilate, Pipoxolan Hydrochloride, Pramiverin, Properidine, Propivane, Propyromazine, Prozapine, Racefemine, Rociverine, Spasmolytol, Stilonium, Tiopramide, Trepibutone, Tricromyl, Trifolium, Trimebutine, *N,N*-1Trimethyl-3,3-diphenyl-propylamine
20

ANTITHROMBOTIC such as Anagrelide, Argatroban, Cilostazol, Daltroban, Defibrotide, Enoxaparin, Fraxiparine®, Indobufen, Lamoparan, Ozagrel, Picotamide, Plafibride, Tedelparin, Ticlopidine, Triflusal

ANTITUSSIVE such as Allocamide, Amicibone, Benproperine, Benzonatate, Bibenzonium, Bromoform, Butamirate, Butethamate, Caramiphen Ethanedisulfonate, Carbetapentane, Chlophedianol, Clobutanol, Cloperastine, Codeine Methyl Bromide, Codeine *N*-Oxide, Codeine
30 Phosphate, Codeine Sulfate, Cyclexanone, Dextromethorphan, Dibunate Sodium, Dihydrocodeine, Dihydrocodeinone Enol Acetate, Dimemorfan, Dimethoxanate, α,α -Diphenyl-2-piperidinepropanol, Dropropizine, Drotebanol, Eprazinone, Ethyl Dibunate, Ethylmorphine,
35 Fominoben, Guaiapate, Hydrocodone, Isoaminile, Levopropoxyphene, Morclofone, Narceine, Normethadone, Noscapine, Oxeladin, Oxolamine, Pholcodine, Picoperine,

Pipazethate, Piperidione, Prenoxdiazine, Racemethorphan,
Taziprinone Hydrochloride, Tipepidine, Zipeprol

ANTIULCERATIVE such as Aceglutamide Aluminum Complex,
 ϵ -Acetamidocaproic Acid Zinc Salt, Acetoxolone,

5 Arbaprostil, Benexate Hydrochloride, Bismuth Subcitrate
Sol (Dried), Carbenoxolone, Cetraxate, Cimetidine,
Enprostil, Esaprazole, Famotidine, Ftaxilide, Gefarnate,
Guaiazulene, Irsogladine, Nizatidine, Omeprazole,
Ornoprostil, γ -Oryzanol, Pifarnine, Pirenzepine,
10 Plaunotol, Ranitidine, Rioprostil, Rosaprostol,
Rotraxate, Roxatidine Acetate, Sofalcone, Spizofurone,
Sucralfate, Teprenone, Trimoprostil, Thrithiozine,
Troxipide, Zolimidine

ANTIUROLITHIC such as Acetohydroxamic Acid, Allopurinol,
15 Potassium Citrate, Succinimide

ANTIVENIN such as Lyovac® Antivenin

ANTIVIRAL

Purines/Pyrimidinones such as 2-Acetyl-pyridine 5-
((2-pyridylamino)thiocarbonyl) Thiocarbonohydrazone,
20 Acyclovir, Dideoxyadenosine, Dideoxycytidine,
Dideoxyinosine, Edoxudine, Floxuridine, Ganciclovir,
Idoxuridine, MADU, Pyridinone, Trifluridine, Vidrarbine,
Zidovudine

Others such as Acetylleucine Monoethanolamine,
25 Acridinamine, Alkylisooxazoles, Amantadine, Amidinomycin,
Cuminaldehyde Thiosemicarbazone, Foscarnet Sodium,
Kethoxal, Lysozyme, Methisazone, Moroxydine,
Podophyllotoxin, Ribavirin, Rimantadine, Stallimycin,
Statolon, Thymosins, Tromantadine, Xenazoic Acid

30 **ANXIOLYTIC**

Arylpiperazines such as Buspirone, Gepirone,
Ipsapirone

Benzodiazepine Derivatives Alprazolam, Bromazepam,
Camazepam, Chlordiazepoxide, Clobazam, Clorazepate,
35 Chotiazepam, Cloxazolam, Diazepam, Ethyl Loflazepate,
Etizolam, Fluidazepam, Flutazolam, Flutoprazepam,
Halazepam, Ketazolam, Lorazepam, Loxapine, Medazepam,

Metaclazepam, Mexazolam, Nordazepam, Oxazepam, Oxazolam, Pinazepam, Prazepam, Tofisopam

Carbamates such as Cyclarbamate, Emylcamate, Hydroxyphenamate, Meprobamate, Phenprobamate, Tybamate

5 **Others** Alpidem, Benzoctamine, Captodiamine, Chlormezanone, Etifoxine, Fluoresone, Glutamic Acid, Hydroxyzine, Mecloralurea, Mephenoxalone, Oxanamide, Phenaglycodol, Suriclone

BENZODIAZEPINE ANTAGONIST such as Flumazenil

10 **BRONCHODILATOR**

Ephedrine Derivatives such as Albuterol, Bambuterol, Bitolterol, Carbuterol, Clenbuterol, Clorprenaline, Dioxethedrine, Eprozinol, Etafedrine, Ethylnorepinephrine, Fenoterol, Hexoprenaline, 15 Isoetharine, Isoproterenol, Mabuterol, Metaproterenol, N-Methylephedrine, Pirbuterol, Procaterol, Protokylol, Reproterol, Rimiterol, Soterenol, Terbutaline, Tulobuterol

Quaternary Ammonium Compounds such as Clutropium Bromide, Oxitropium Bromide

20 **Xanthine Derivatives** such as Acefylline, Acefylline Ambuphylline, Aminophylline, Bamifylline, Choline Theophyllinate, Doxofylline, Dyphylline, Enprofylline, Etamiphyllin, Etofylline, Guaithylline, 25 Proxyphylline, Theobromine, 1-Theobromineacetic Acid, Theophylline

Others such as Methoxyphenanime, Tretoquinol

CALCIUM CHANNEL BLOCKER

Arylalkylamines such as Bepridil, Diltiazem, 30 Fendiline, Gallopamil, Terodiline, Verapamil

Dihydropyridine Derivatives such as Felodipine, Isradipine, Nicardipine, Nifedipine, Nilvadipine, Nimodipine, Nisoldipine, Nitrendipine

Piperazine Derivatives such as Flunarisine

35 **Others** such as Perhexiline

CALCIUM REGULATOR such as Calcifediol, Calcitonin, Calcitriol, Clodronic Acid, Dihydrotachysterol,

- Elcatonin, Etidronic Acid, Ipriflavone, Pamidronic Acid, Parathyroid Hormone, Teriparatide Acetate
- CARDIOTONIC** such as Acetyldigitoxins, 2-Amino-4-picoline, Amrinone, Bucclasdesine, Cerberoside,
- 5 Camphotamide, Convallatoxin, Cymarin, Denopamine, Deslanoside, Ditalin, Digitalis, Digitoxin, , Digoxin, Dobutamine, Dopamine, Dopexamine, Enoximone, Erythrophleine, Fenalcomine, Gitalin, Gitoxin, Glycocyamine, Heptaminol, Hydrastinine, Lanotodises,
- 10 Metamivam, substituted Methoxyphenyl-4,5-dihydro-3(2H)-pridazinones, Milrinone, Neriifolin, Oleandrin, Ouabain, Oxyfedrine, Prenalterol, Proscillaridin, Resibufogenin, Scillaren, Scillarenin, Strophanthin, Sulmazole, Theobromine, Xamoterol
- 15 **CHELATING AGENT** such as Deferozmine, Edetate Calcium Disodium, Edetate Disodium, Edeate Sodium, Edetate Trisodium, Pentetate Calcium Trisodium, Pentectic Acid, Succimer, Trientine
- CHOLECYSTOKININ ANTAGONIST (CCK Antagonist)**
- 20 **CHOLELITHOLYTIC AGENT** such as Chenodiol, Methyl tert-Butyl Ether, Monooctanoin, Ursodiol
- CHOLERETIC** such as Alibendol, Anethole Trithion, Azintamide, Cholic Acid, Cicrotoic Acid, Clanobutin, Cyclobutyrol, Cyclovalone, Cynarin(e), Dehydrocholic
- 25 Acid, Deoxycholic Acid, Dimecrotic Acid, α -Ethylbenzyl Alcohol, Exiproben, Feguprol, Fencibutirol, Fenipentol, Florantyrone, Hymecromone, Menbutone, 3-(o-Methoxyphenyl)-2-phenylacrylic Acid, Metochalcone, Moquizone, Osalmid, Ox Bile Extract, 4,4'-Oxydi-2-
- 30 butanol, Piprozolin, Prozapine, 4-Salicyloylmorpholine, Sincalide, Taurocholic Acid, Timonacic, Tocamphyl, Trepibutone, Vanitiolide
- CHOLINERGIC** such as Aceclidine, Acetylcholine, Acetylcholide, Aclatonium Napadisilate, Benzpyrinium
- 35 Bromide, Bethanechol, Carbachol, Carpronium, Demecarium, Dexpanthenol, Diisopropyl Paraaxon, Echothiophate, Edrophonium, Eseridine, Furtrethonium, Isoflurophate,

- Methacholine Chloride, Muscarine, Neostigmine,
Oxapropanium, Physostigmine, Pyridostigmine
CHOLINESTERASE INHIBITOR such as Ambenonium, Distigmine,
Galanthamine
- 5 **CHOLINESTERASE REACTIVATOR** such as Obidoximine,
Pralidoxime
CNS STIMULANT/AGENT such as Amineptine, Amphetimine,
Amphetaminil, Bemegride, Benzphetamine, Brucine,
Caffeine, Chlorphentermine, Clofenciclan, Clortermine,
10 Coca, Demanyl Phosphate, Dexoadrol, Dextroamphetamine
Sulfate, Diethylpropion, N-Ethylamphetamine, Ethamivan,
Etifelmin, Etryptamine, Fencamfamine, Fenethylline,
Fenosolone, Flurothyl, Hexacyclonate Sodium, Homocamfin,
Mazindol, Megexamide, Methamphetamine, Methylphenidate,
15 Nicotine, Nicotinic Agonist, Nikethamide, Pemoline,
Pentylene-tetrazole, Phenidimetrazine, Phenmetrazine,
Phentermine, Picrotoxin, Pipradrol, Prolintane,
Pyrovalerone, Tetrahydrobenzothienopyridines
DECONGESTANT such as Cafaminol, Nordefrin
- 20 **DENTAL CARRIES PROPHYLACTIC** such as Sodium Fluoride
DEPIGMENTOR such as Hydroquinine, Hydroquinone,
Monobenzene
DIURETIC
Organomercurials such as Chlormerodrin, Meralluride,
25 Mercamphamide, Mercaptomerin Sodium, Mercumallylic Acid,
Mercumatilin Sodium, Mercurous Chloride, Mersalyl
Pteridines such as Furterene, Triamterene
Purines such as 7-Morpholinomethyltheophylline,
Pamabrom, Protheobromine, Theobromine
- 30 **Steroids** such as Canrenone, Oleandrin, Spironolactone
Sulfonamide Derivatives such as Acetazolamide,
Azosemide, Bumetanide, Butazolidine, Chloraminophenamide,
Clofenamide, Clorexolene, Diphenylmethane-4,4'-
disulfonamide, Disulfamide, Ethoxzolamide, Flumethiazide,
35 Mefruside, Methazolamide, Piretanide, Torasemide
Uracils such as Aminometradine, Amisometradine

Others such as Amanozine, Amiloride, Arbutin, Chlorazanyl, Ethacrynic Acid, Etazolol, Isosorbide, Mannitol, Metochalcone, Perhexiline, Urea

5 **DOPAMINE RECEPTOR AGONIST** such as Bromocriptine, Fenoldopam, Lisuride, Naxagolide, Pergolide

ECTOPARASITICIDE such as Amitraz, Benzyl Benzoate, Carbaryl, Crothamiton, DDT, Dixanthogen, Isobornyl Thiocyanacetate (Technical), Lime Sulfurated Solution, Lindane, Malathion, Mercuric Oleate, Sulphur
10 (Pharmaceutical)

ENZYME

Digestive such as α -Amylase (Swine Pancreas), Lipase, Pancrelipase, Pepsin, Rennin

Penicillin Inactivating such as Penicillinase

15 **Proteolytic** such as Collagenase, Chymopapain, Chymotrypsins, Papain, Trypsin

ENZYME INDUCER (HEPATIC) such as Flumecinol

ESTROGEN

20 **Nonsteroidal** such as Benzestrol, Broparoestrol, Chlorotrianisene, Dienestrol, Diethylstilbestrol, Diethylstilbestrol Dipropionate, Dimestrol, Fosfestrol, Hexestrol, Methallenestril, Methestrol

Steroidal such as Colpormon, Conjugated Estrogenic Hormones, Equilenin, Equilin, Esterified Estrogens,
25 Esteropipate,

17 β -Estradiol, Estradiol, Estradiol Benzoate, Estradiol 17 β -Cypionate, Estriol, Estrone, Ethinyl Estradiol, Mestranol, Moxestrol, Mytatrienediol, Polyestradiol Phosphate, Quinestradiol, Quinestrol

30 **GASTRIC SECRETION INHIBITOR** such as Enterogastrone, Octreotide

GLUCOCORTICOID such as 21-Acetoxypropfenolone, Aalclometasone, Algestone, Amcinonide, Beclomethasone, Betamethasone, Betamethasone Dipropionate, Budesonide,
35 Chloroprednisone, Clobetasol, Blovetasone, Clocortolone, Cloprednol, Corticosterone, Cortisone, Cortivazol, Deflazacort, Desonide, Desoximetasone, Dexamethasone, Diflorasone, Diflucortolone, Difluprednate, Enoxolone,

- Fluazacort, Flucloronide, Flumehtasone, Flunisolide, Fluocinolone Acetonide, Fluocinonide, Fluocortin Butyl, Fluocortolone, Fluorometholone, Fluperolone Acetate, Fluprednidene Acetate, Fluprednisolone, Flurandrenolide, Formocortal, Halcinonide, Halometasone, Halopredone Acetate, Hydrocortamate, Hydrocortisone, Hydrocortisone Acetate, Hydrocortisone Phosphate, Hydrocortisone 21-Sodium Succinate, Hydrocortisone Tebutate, Mazipredone, Medrysone, Meprednisone, Methyolprednisolone, Mometasone Furoate, Paramethasone, Prednicarbate, Prednisolone, Prednisolone 21-Diethylaminoacetate, Prednisone Sodium Phosphate, Prednisolone Sodium Succinate, Prednisolone Sodium 21-*m*-Sulfobenzoate, Prednisolone 21-Stearoylglycolate, Prednisolone Tebutate, Prednisolone 21-Trimethylacetate, Prednisone, Prednival, Prednylidene, Prednylidene 21-Diethylaminoacetate, Tixocortal, Triamcinolone, Triamcinolone Acetonide, Triamcinolone Benetonide, Triamcinolone Hexacetonide
- GONAD-STIMULATING PRINCIPLE** such as Clomiphene, Cyclofenil, Epimestrol, FSH, HCG, LH-RH
- GONADOTROPIC HORMONE** such as LH, PMSG
- GROWTH HORMONE INHIBITOR** such as Somatostatin
- GROWTH HORMONE RELEASING FACTOR** such as Semorelin
- GROWTH STIMULANT** such as Somatotropin
- HEMOLYTIC** such as Phenylhydrazine
- HEPARIN ANTAGONIST** such as Hexadimethrine, Protamines
- HEPATOPROTECTANT** such as Betaine, Citolone, Malotilate, Orazamide, Phosphorylcholine, Protoporphyrin IX, Silymarin-Group, Thiolic Acid
- IMMUNOMODULATOR** such as Amiprilose, Bucillamine, Ditiocarb Sodium, Inosine Pranobex, Muroctasin, Platonin, Procodazole, Tetramisole, 6-aryl-5,6-dihydroimidazol-(2,1-B) Thiazole Derivatives, Thymomodulin, Thymopentin
- IMMUNOSUPPRESSANT** such as Cyclophilin, Cyclosporins, FK-506, Mizoribine, Rapamycin, Rapamycin Sulfamates
- ION EXCHANGE RESIN** such as Carbacrylic Resins, Resodec, Sodium Polystyrene Sulfonate

- LACTATION STIMULATING HORMONE** such as Prolactin
- LH-RH AGONIST** such as Buserelin, Goserelin, Leuprolide, Nafarelin, Triptorelin
- LIPOTROPIC** such as N-Acetylmethionine, Choline Chloride,
- 5 Choline Dehydrocholate, Choline Dihydrogen Citrate, Inositol, Lecithin, Methionine
- LUPUS ERYTHEMATOSUS SUPPRESSANT** such as Bismuth Sodium Triglycollamate, Bismuth Subsalicylate
- MINERALOCORTICOID** such as Aldosterone,
- 10 Deoxycorticosterone, Fludrocortisone
- MIOTIC** such as Pilocarpus
- MONOAMINE OXIDASE INHIBITOR** such as Phenoxypropazine, Pivalylbenzhydrazine
- MUCOLYTIC** such as Acetylcysteine, Bromhexine,
- 15 Carbocysteine, Domiodol, Letosteine, Mecysteine, Mesna, Sobrerol, Stepronin, Tiopronin, Tyloxapol
- MUSCLE RELAXANT (SKELETAL)** such as Afloqualone, Alcuronium, Atracurium Besylate, Baclofen, Benzoquinonium, C-Calebassine, Carisoprodol,
- 20 Chlorphenesin Carbamate, Chlozoxazone, Curare, Cyclobenzaprine, Dantrolene, Decamethonium, Eperisone, Fazadinium, Flumetramide, Gallamine Triethiodide, Hexacarbacholine, Hexafluorenium, Idrocilamide, Lauexium Methyl Sulfate, Leptodactyline, Memantine, Mephenesin,
- 25 Metaxalone, Methocarbamol, Metocurine Iodide, Pancuronium, Pipecurium, Promoxolane, Quinine Sulfate, Styramate, Succinylcholine, Succinylcholine Suxethonium Bromide, Tetrazepam, Thiocolchicoside, Tizanidine, Tolperisone, Tubocurarine, Vecuronium, Zoxolamine
- 30 **NARCOTIC ANTAGONIST** such as Amiphenazole, Cyclazocine, Levallorphan, Nadide, Nalmafene, Nalorphine, Nalorphine Dinicotinate, Naloxone, Naltrexone
- NEUROPROTECTIVE** such as Dizocilpine
- NOOTROPIC** such as Aceglutamide, Acetylcarnitine,
- 35 Aniracetam, Bifematlane, Exifone, Fipexide, Idebenone, Indeloxazone, Nizofenone, Oxiracetam, Piracetam, Propentofylline, Pyritinol
- OPHTHALMIC AGENT** such as 15-ketoprostaglandins

- OVARIAN HORMONE such as Relaxin
- OXYTOCIC such as Carboprost, Cargutocin, Deaminooxytocin, Ergonovine, Gemeprost, Methylergonovine, Oxytocin, Pituitary (Posterior), Prostaglandin E₂, Prostaglandin
- 5 F_{2α}, Sparteine
- PEPSIN INHIBITOR such as Sodium Amylosulfate
- PERISTALTIC STIMULANT such as Cisapride
- PROGESTOGEN such as Allylestrenol, Anagestone, Chlormadinone Acetate, Delmadinone Acetate, Demegestone,
- 10 Desogestrel, Dimethisterone, Dydrogesterone, Ethinylestrenol, Ethisterone, Ethynodiol, Ethynodiol Diacetate, Flurogestone Acetate, Gestodene, Gestonorone Caproate, Haloprogesterone, 17-Hydroxy-16-methylene--progesterone, 17α-Hydroxyprogesterone,
- 15 17α-Hydroxygesterone Caproate, Lynestrenol, Medrogestone, Medroxyprogesterone, Megestrol Acetate, Melengestrol, Norethindrone, Norethindrone Acetate, Norethynodrel, Norgesterone, Norgestimate, Norgestrel, Norgestrienone, 19-Norprogesterone, Norvinisterone, Pentagestrone,
- 20 Progesterone, Promegestone, Quingestron, Trengestone
- PROLACTIN INHIBITOR such as Metergoline
- PROTAGLANDIN/PROTAGLANDIN ANALOG such as Bemeprost, Prostacyclin, Prostaglandin E₁, Sulprostone
- PROTEASE INHIBITOR such as Aprotinin, Camostat, Gabexate,
- 25 Nafamostat
- RESPIRATORY STIMULANT such as Almitrine, Dimeflin, Dimorpholamine, Doxapram, Lobeline, Mepixanox, Pimeclone, Sodium Succinate, Tacrine
- SCLEROSING AGENT such as Ethanolamine, Ethylamine, 2-
- 30 Hexyl-
- decanoic Acid, Sodium Ricinoleate, Sodium Tetradecyl Sulfate, Tribenoside
- SEDATIVE/HYPNOTIC
- Acyclic Ureides such as Acecarbromal, Apronalide,
- 35 Bomisovalum, Capuride, Carbromal, Ectylurea
- Alcohols such as Chlorhexadol, Ethchlorvynol, 4-Methyl-5-thiazoleethanol, tert-Pentyl Alcohol, 2,2,2-Trichloroethanol

Amides such as Butoctamide, Diethylbromoacetamide, Ibrotamide, Isovaleryl Diethylamide, Niaprazine, Tricetamide, Trimetozine, Zolpidem, Zopiclone

Barbituric Acid Derivatives such as Allobarbital, 5 Amobarbital, Aprobarbital, Barbital, Brallabarbital, Butabarbital Sodium, Butalbital, Butallylonal, Butethal, Carbutarb, Cyclobarbital, Cyclopentobarbital, Enallylpropymal, 5-Ethyl-5-(1-piperidyl) barbituric Acid, 5-Furfuryl-5-isopropylbarbituric Acid, Heptabarbital, 10 Hexethal Sodium, Hexobarbital, Mephobarbital, Methitural, Narcobarbital, Nealbarbital, Pentobarbital Sodium, Phenallymal, Phenobarbital, Phenobarbital Sodium, Phenylmethylbarbituric Acid, Probarbital, Propallylonal, Proxibarbal, Reposal, Secobarbital Sodium, Talbutal, 15 Tetrabarbital, Vinbarbital Sodium, Vinylbital

Benzodiazepine Derivatives such as Brotizolam, Doxefazepam, Estazolam, Flunitrazepam, Flurazepam, Haloxazolam, Loprazolam, Lormetazepam, Nitrazepam, Quazepam, Temazepam, Triazolam

20 **Bromides** such as Ammonium Bromide, Calcium Bromide, Calcium Bromolactobionate, Lithium Bromide, Magnesium Bromide, Potassium Bromide, Sodium Bromide

Carbamates such as Amyl Carbamate (Tertiary), Ethinamate, Hexaprypymate, Meparfynol Carbamate, Novonal, 25 Trichlorourethan

Chloral Derivatives such as Carbocloral, Chloral Betaine, Chloral Formamide, Chloral Hydrate, Chloralantipyrine, Dichloralphenazone, Pentaerythritol Chloral, Triclofos

30 **Piperidinediones** such as Glutehimide, Methyprylon, Piperidione, Pyrithyldione, Taglutimide, Thalidomide

Quinazalone Derivatives such as Etaqualone, Mecloqualone, Methaqualone

Others such as Acetal, Acetophenone, Aldol, Ammonium 35 Valerate, Amphenidone, d-Bornyl α -Bromoisovalerate, d-Bornyl Isovalerate, Bromoform, Calcium 2-Ethylbutanoate, Carfinat, α -Chlorolose, Clomethiazole, Cypripedium, Doxylamine, Etodroxizine, Etomidate, Fenadiazole,

- Homofenazine, Hydrobromic Acid, Mecloxamine, Menthyl Valerate, Opium, Paraldehyde, Perlapine, Propiomazine, Rilamazafone, Sodium Oxybate, Sulfonethylmethane, Sulfonmethane
- 5 **THROMBOLYTIC** such as APSAC, Plasmin, Pro-Urokinase, Streptokinase, Tissue Plasminogen Activator, Urokinase
THYROTROPIC HORMONE such as TRH, TSH
URICOSURIC such as Benzbromarone, Ethebenecid, Orotic Acid, Zoxazolamine
- 10 **VASODILATOR (CEREBRAL)** such as Bencyclane, Ciclonicate, Cinnarizine, Citicoline, Diisopropylamine Dichloractetate, Eburnamonine, Fenoxedil, Ibudilast, Ifenprodil, Nafronyl, Nicametate, Nicergoline, Nimodipine, Papaverine, Pentifylline, Tinofedrine,
- 15 Vincamine, Vinpocetine
VASODILATOR (CORONARY) such as Amotriphene, Bendazol, Benfurodil Hemisuccinate, Benziocardone, Chloacizine, Chromonar, Clobenfurol, Clonitrate, Dilazep, Dipyridamole, Droprenilamine, Efloxate, Erythritol,
- 20 Erythrityl Tetranitrate, Etafenone, Floredil, Ganglefene, Hexestrol Bis(β -diethylaminoethyl ether), Hexobendine, Isosorbitol Dinitrate, Itramin Tosylate, Khellin, Lidoflazine, Mannitol Hexanitrate, Medibazine, Nicorandil, Nitroglycerin, Pentaerythritol Tetranitrate,
- 25 Pentrinitrol, Pimefylline, Potassium Nitrite, Prenylamine, Propatyl Nitrate, Pyridofylline, Trapidil, Tricromyl, Trimetazidine, Trolnitrate Phosphate, Visnadine
VASODILATOR (PERIPHERAL) such as Bamethan, Betahistine,
- 30 Bradykinin, Brovincamine, Bufoniode, Buflomedil, Butalamine, Cetiedil, Ciclonicate, Cinepazide, Cyclandelate, Eledoisin, Heronicate, Inositol Niacinate, Isoxsuprine, Kallidin, Kallikrein, Moxisylyte, Nicofuranose, Nicotiny Alcohol, Nylidrin,
- 35 Pentoxifylline, Piribedil, Suloctidil, Xanthinal Niacinate
VASOPROTECTANT such as Benzarone, Bioflavonoids, Chromocarb, Clobeoside, Diosmin, Dobesilate Calcium,

Escin, Rolescutol, Leucocyanidin, Metescufylline,
Quercetin, Rutin, Troxerutin

VITAMIN/VITAMIN SOURCE/EXTRACTS such as Vitamins A, B, C,
D, E, and K and derivatives thereof, Calciferols,
5 Glycyrrhiza, Mecobalamin

VULNERARY such as Allantoin, Asiaticoside, Cadexomer
Iodine, Chitin, Dextranomer

10 The above list of pharmaceutical agents is based upon
the list provided in *The Merk Index*, 11th Edition, Merck
& Co. Rahway, N.J. (1989). Moreover, the above drugs may
be used either in the free form or, if capable of forming
salts, in the form of a salt with a suitable acid or
base; if the drug has a carboxyl group, its esters may
also be employed.

What is claimed is:

1. A flexible, finite, bioadhesive composition for topical application comprising:

5 (a) a therapeutically effective amount of at least one pharmaceutically active agent;

(b) a pharmaceutically acceptable solvent for the pharmaceutically active agent and a plasticizer;

10 (c) in admixture with the pharmaceutically active agent in the solvent, a pharmaceutically acceptable bioadhesive carrier; and,

(d) a cohesive increasing amount of a clay;

wherein the composition is substantially free of water, substantially water insoluble and is a bioadhesive; and wherein the pharmaceutically active agent is present in non-crystallized form in the composition.

2. The composition of claim 1, wherein the pharmaceutically acceptable solvent is in an amount from about 20 to about 50 weight percent based on the weight of the whole composition, of which the plasticizer represents about 10 to about 30 weight percent based on the weight of the whole composition, the bioadhesive carrier is in an amount from about 20 to about 50 weight percent and the clay represents about 0.5 to 20% based on the weight of the whole composition.

3. The composition of claim 1, wherein the pharmaceutically active agent is at least one local anesthetic in an amount of about 10 to 40 weight percent based on the weight of the total composition.

30 4. The composition of claim 1, wherein the pharmaceutically active agent is from a class of drugs selected from the group consisting of analgesic anti-inflammatory drugs, central nervous system drugs, antihistaminic or antiallergic drugs, acitonide anti-inflammatory drugs, androgenic and estrogenic steroids, respiratory drugs, sympathomimetic drugs, antimicrobial drugs, antihypertensive drugs, cardiotonic drugs, coronary vasodilators, vasoconstrictors, beta blocking

and antiarrhythmic drugs, calcium antagonistic and other circulatory anticonvulsants, anti-vertigo-tranquilizing drugs, antipsychotic drugs, muscle-reactants drugs, anti-Parkinson drugs, non-steroidal hormones, anti-hormones, vitamins, anti-tumor, enzymes, herb medicines or crude extracts, miotics, cholinergic agonists, antimuscarinic or muscarinic cholinergic blocking drugs, mydriatics, psychic energizers, humoral agents, antispasmodic drugs, antidepressants, antidiabetics, anorexic drugs, anti-allergic drugs, decongestants, antipyretics, anti-migraine drugs, antimalarial, antiulcer drugs, peptides, and anti-estrogens.

5. The composition of claim 4, in which the pharmaceutically active agent is one or more steroids selected from the group consisting of androgenic steroids, including testosterone; methyltestosterone; fluoxymesterone; estrogenic steroids, including conjugated estrogens, esterified estrogens, estropipate, 17 β -estradiol, 17 β -estradiol esters such as 17 β -estradiol valerate, equilin, mestranol, estrone, estriol; 17 β -estradiol derivatives such as 17 β -ethinyl estradiol; diethylstilbestrol, progestational agents, including progesterone and progesterone analogs such as 19-norprogesterone, hydroxyprogesterone caproate, 17 α -hydroxyprogesterone, dydrogesterone, medroxyprogesterone acetate; and norethindrone, norethindrone acetate, melengestrol, chlormadinone; ethynodiol diacetate, norethynodrel, dydrogesterone, dimethisterone, ethinylestrenol, norgestrel, demegestone, promegestone, megestrol acetate, anti-estrogen and anti-androgenic steroids.

6. The composition of claim 3, wherein the anesthetic agent is selected from the group consisting of procaine, lidocaine, prilocaine, mepivacaine, dyclonine, dibucaine, benzocaine, chlorprocaine, tetracaine, bupivacaine, and etidocaine and is in the form of the base or an acid-addition salt or both forms.

7. The composition of claim 6, wherein the acid-addition salt is hydrochloride.

8. The composition of claim 1, wherein the bioadhesive is selected from the group consisting of gums and celluloses.

9. The composition of claim 8, wherein the gum is selected from the group consisting of karaya gum, tragacanth gum, pectin gum, xanthan gum, guar gum, cellulose, and cellulose derivatives.

10. The composition of claim 3, wherein the solvent for the anesthetic agent is at least one polyhydric alcohol.

11. The composition of claim 10, wherein the polyhydric alcohol is a polyalkylene glycol.

12. The composition of claim 11, wherein the glycol is selected from the group consisting of dipropylene glycol, propylene glycol, ethylene glycol, polyethylene glycol, glycerin, butylene glycol, hexylene glycol, polypropylene glycol, and sorbitol.

13. The composition of claim 1 further comprising a backing material conforming to the size and shape of a single dosage of the composition.

14. The composition of claim 1 comprising about 20 to 35 weight percent of karaya gum, about 20 to 40 weight percent of at least one glycol, about 10 to 25 weight percent of lidocaine base, and 1 to 7 percent smectite clay, and further comprising a binder in an amount sufficient to bind the other ingredients.

15. The composition of claim 14 comprising about 10 weight percent of karaya gum, about 13 weight percent of at least one glycol, and about 8 weight percent of lidocaine base, and further comprising a binder in an amount sufficient to bind the other ingredients.

16. The composition of claim 14 comprising about 7 weight percent of karaya gum, about 13 weight percent of at least one glycol, and about 8 weight percent of lidocaine base, and further comprising a binder in an amount sufficient to bind the other ingredients.

17. The composition of claim 14 comprising about 5 weight percent of karaya gum, about 13 weight percent of at least one glycol, and about 8 weight percent of lidocaine base, 2 percent Bentonite, and further
5 comprising a binder in an amount sufficient to bind the other ingredients.

18. The composition of claim 14 comprising about 5 weight percent of karaya gum, about 13 weight percent of at least one glycol, and about 8 weight percent of
10 lidocaine base, 2 percent Bentonite, and further comprising a binder in an amount sufficient to bind the other ingredients.

19. The composition of claim 1, wherein the pharmaceutically active agent is an anti-microbial agent.

15 20. The composition of claim 19, wherein the anti-microbial agent is an antifungal agent.

21. The composition of claim 20, wherein the anti-microbial agent is clotrimazole.

22. The composition of claim 20, wherein the
20 antimicrobial agent is miconazole.

23. A method of administering one or more pharmaceutically active agents to a subject comprising the steps of:

25 providing the composition set forth in claim 1; and contacting an area of skin or mucous membrane with the composition to administer the pharmaceutically active agent.

24. The method of claim 21, wherein the pharmaceutically active agent is an anesthetic agent
30 selected from the group consisting of procaine, dyclonine, lidocaine, prilocaine, mepivacaine, benzocaine, propoxycaine, chloroprocaine, tetracaine, bupivacaine, etidocaine, and dibucaine.

25. The method of claim 22, wherein the anesthetic
35 agent is administered in the form of a free base.

26. The method of claim 22, wherein the anesthetic agent is administered in the form of an acid-addition salt.

27. The method of claim 22, wherein the solvent is at least one polyhydric alcohol.